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ABSTRACT 
A well-known function of Growth Hormone (GH) is the regulation of postnatal 
longitudinal growth but it also affects other biological processes, for instance 
metabolism and inflammation. Actions of GH are tightly regulated at several levels and 
by several different factors and are initiated by GH binding to membrane bound GH 
receptors (GHR). The intracellular signaling of GH and other related hormones and 
cytokines is predominately mediated by the JAK-STAT pathway. This pathway is 
regulated in a negative feedback manner by the Suppressors of Cytokine Signaling 
(SOCS) family of proteins. One of the family members, SOCS2, is intimately tied to 
GH by virtue of the phenotype that results from its absence. SOCS2-/- mice are 40% 
larger than wildtype littermates due to increased GH sensitivity.  
 
Here, the molecular mechanism behind SOCS2s negative regulation of GH signaling, 
and its effects on metabolism and inflammation are described. We demonstrate that 
SOCS2 assembles a canonical E3 ubiquitin ligase complex with Elongin B, Elongin C, 
Cullin 5 and Rbx2 and that this complex has intrinsic E3 ligase activity in vitro. 
Overexpression of SOCS2 and its complex members leads to ubiquitination and 
proteasomal degradation of the GHR. We also outline the importance of the different 
domains of SOCS2, and demonstrate the necessity of the SOCS-box for proper SOCS2 
activity. In a follow up study the claim that the naturally occurring Ser52Asn 
polymorphism of SOCS2 affects its activity and may contribute to acromegaly in 
humans was investigated. The Ser52Asn mutant was however found to be as efficient 
at regulating GH signaling as the wildtype and we conclude that it is unlikely to 
contribute to increased GH sensitivity. In Paper III the phenotype of SOCS2-/- mice 
under conditions of dietary stress is described. We report that SOCS2 deletion protects 
against high fat diet (HFD) induced hepatic steatosis but simultaneously leads to 
decreased insulin sensitivity. SOCS2-/- mice were found to have increased triglyceride 
output from the liver but also increased plasma levels of proinflammatory cytokines 
without apparent macrophage infiltration. In vitro examination of macrophages 
revealed increased phagocytic activity and cytokine production in the absence of 
SOCS2 and suggests a direct role for SOCS2 in the regulation of TLR4 signaling. 
Finally, the results of a screening effort to identify SOCS2-modulating, drug-like 
molecules are included. We have identified a prospective hit that binds to and inhibits 
SOCS2 activity in vitro. In summary, SOCS forms an E3 ligase complex which targets 
the GHR for degradation. This forms the molecular basis of its physiological actions. 
SOCS2-/- mice are protected from HFD induced hepatic steatosis but suffer from 
deteriorated insulin sensitivity related to increased inflammation.             
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1 INTRODUCTION 
Higher organisms are composed of a multitude of cells with diverse functions that are 
secluded into specific organs in the body. Essential for the survival and proper 
functioning of the organism is the existence of a reliable system for communication 
between the cells, both within and between various organs. One method for 
intercellular communication is the secretion of molecules from one cell that migrate to 
and trigger a response in a target cell. Hormones constitute one class of such molecules. 
They are secreted from specialized organs within the body, travel through the 
bloodstream to their target tissue where they elicit a response by binding to their 
respective receptors. Signaling substances that are secreted locally within one organ or 
tissue are usually referred to as cytokines. Hormones and cytokines regulate a plethora 
of bodily functions including reproduction, metabolism, immune responses, growth and 
development.  
 
The importance of well-functioning intercellular and endocrine signaling is highlighted 
by the association between perturbations of hormonal signaling and endocrine 
disorders. Several of these conditions are caused by or associated with a lack or excess 
of a particular hormone but of equal importance is that the target cells have an adequate 
response to the stimuli. Aberrations in intracellular signaling cascades can produce 
syndromes similar to lack of hormones e.g. type 2 diabetes and Laron syndrome or to 
excess of hormones e.g. polycythemia vera.  
 
To ensure proper responses to external stimuli cells have developed several 
mechanisms for regulation and propagation of intracellular signaling. Some are broad 
and cover many pathways while some are more specific in their actions. Modes of 
regulation include degradation of receptors and signaling intermediates, de-activating 
events such as de-phosphorylation, competitive binding and seclusion of signaling 
components into intracellular organelles. An interesting family of intracellular 
regulators is the Suppressors of Cytokine Signaling (SOCS). SOCS proteins regulate 
the signaling of several hormones and cytokines. This thesis is concerned with the 
actions of SOCS2, a known regulator of the actions of Growth Hormone (GH). The 
role of GH in biological processes and pathological conditions has been investigated for 
almost a century. The pleiotropic actions that have been described underscore its 
importance and motivate further studies of the regulators of GH and their actions in the 
body and on the cellular level.   
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1.1 GROWTH HORMONE 
The existence of growth promoting substances produced by the anterior pituitary gland 
was shown in 1921 by Evans and Long when they managed to induce gigantism by 
repeatedly injecting rats with an emulsion of the gland intraperitoneally [1]. Almost a 
quarter of a century later, in 1944, Evans and Li isolated growth hormone from bovine 
pituitaries for the first time [2]. Human GH (hGH) was isolated a decade later [3] and 
the first successful treatment of a patient with short stature using human GH was done 
by Maurice Raben in the late 1950’s [4,5].   
 
Growth hormone, also known as somatotropin, somatropin or somatotrope hormone, 
belongs to the same family of hormones as the prolactins (PRL) and placental lactogens 
(PL, also known as chorionic somatomammotropin (CS)) [6]. GH is a polypeptide 
hormone and in its most prevalent form it has a size of 22 kDa and contains 191 amino 
acids in humans. The protein structure was solved in 1987 and it showed that the GH 
protein molecule consists of four α-helices that are arranged in an up-up-down-down 
fashion and that the helices are further joined by two disulfide bridges [7]. Two sites for 
GH interaction with its cellular receptor have been identified. Site 1 consists of residues 
54 to 74 located in a loop region between the first and second helix, and the C-terminal 
part which contains parts of the forth helix [8]. Site 2 is located on the opposite side of 
the GH molecule and consists of the N-terminal part, corresponding to the start of the 
first helix, and the latter part of the third helix [9].  
 
Replacement of hGH residue Gly120 with an arginine creates a GH antagonist since the 
residue is located on the third helix in site 2 and replacement with a bulky residue 
abrogates the binding to a tryptophan on the Growth Hormone Receptor (GHR). Since 
site 1 is left intact the antagonist still interacts with the GHR but fails to initiate further 
downstream signaling and thus acts as a competitive antagonist [10,11]. This receptor 
antagonist has been further modified by pegylation to increase its half-life in the body, 
and by additional mutations in site 1 that increase its affinity for the GHR, and is now 
used clinically under the name Pegvisomant®, to treat an un-common form of 
acromegaly [12].      
 
The human GH gene is part of a gene cluster of five similar and related genes that have 
evolved from duplications of the same ancestral gene that occurred over 350 million 
years ago. The five genes in the cluster are the GH-normal (GH-N) gene, the GH-
variant (GH-V) gene, the CS-like (CS-L) gene and the CS-A and CS-B genes [13,14]. 
The GH-N gene encodes the predominant form that is secreted from the pituitary while 
GH-V encodes a variant of the hormone that is expressed by the human placenta [15]. 
 
 
1.2 THE GROWTH HORMONE AXIS 
The somatotropic cells of the anterior pituitary gland are the primary producers of GH 
in the body. The production of GH by the somatotrophs is mainly regulated by the 
pituitary transcription factor Pit-1. Translated GH is then stored in secretory granules 
and increased concentrations of cAMP or Ca2+ induces the release of GH from the 
somatotrophs [16-18]. The release and transcription of GH is controlled by two 
peptides secreted by the neuroendocrine cells of the neurosecretory nuclei of the 
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hypothalamus that bind to specific G-protein coupled receptors on the somatotrophs. 
GH production and release is stimulated by Growth Hormone Releasing Hormone 
(GHRH), also known as somatocrinin, and the release is inhibited by Growth Hormone 
Inhibiting Hormone (GHIH), also known as somatostatin. The release of GH from the 
pituitary is largely regulated by the balance of GHRH and GHIH [14,18,19].  
 
GH secretion in humans is pulsatile and plasma levels can vary between 1 and as high 
as 72 ng/ml. GH secretion occurs primarily during sleep but peaks can be observed in 
plasma during the day [20]. The secretion is sexually dimorphic; males have higher 
nocturnal pulses and small pulses during daytime. Women on the other hand have a 
more continuous secretion of GH and more frequent pulses with similar amplitude [21]. 
Sex-different GH secretion patterns seem important for the regulation of sex-specific 
hepatic gene transcription in rodents [22,23] and most likely in humans as well [24]. 
Sex-differences in GH secretory patterns can at least partly explain differences in 
growth between males and females. 
 
Once GH is released into the bloodstream it travels to target organs where it binds to 
the GHR. GHR is ubiquitously present with the highest levels found in the cells of the 
liver. GHR signaling triggers the expression and release if Insulin-like Growth Factor-1 
(IGF-1), also known as somatomedin C, which is a major mediator of somatic GH 
action [25-27].  
 
GH release and production is also negatively regulated by several factors. Both IGF-1 
and GH increase the actions of GHIH and diminish the actions of GHRH and thus act 
in a negative feedback loop that leads to a decreased release of GH [28-30]. Ghrelin, a 
peptide produced by the intestine, stimulates GH release via Growth Hormone 
Secretagogue Receptors (GHS-R) present on the surface of the somatotropic cells 
[31,32]. Other factors that regulate GH release include glycemic levels, exercise, sex 
hormones, glucocorticoids and thyroid hormones [30,33-37].  
 
GH actions are also influenced by a factor known as Growth Hormone Binding Protein 
(GHBP) which is identical to the extracellular domain of the GHR. GHBP is encoded 
by the same gene as the GHR and is produced by proteolytic cleavage of the 
extracellular part of GHR but may also be produced by alternative splicing of the 
mRNA transcript [38,39]. GHBP decreases the availability of the GHR and also 
competes with the receptor for binding to the hormone, this negatively influences GH 
action. However, GHBP also prevents renal clearance of GH, thus prolonging its 
presence in plasma which means it may have both inhibitory and enhancing effects on 
GH actions [40].    
 
 
1.3 SOMATIC EFFECTS OF GROWTH HORMONE 
Growth hormone is mitogenic hormone and its primary somatic effect is the promotion 
of longitudinal growth [14,41]. GH promotes the proportional growth of several organs 
in the body including liver, muscle, bone and adipose tissue and exerts effects on 
cellular differentiation, metabolism and nutrient uptake [42-46]. It is also involved in 
the regulation of immune cells and hematopoiesis [47,48] and can act on the brain to 
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influence emotion, behavior and other cognitive responses [49,50]. GH actions are 
pleiotropic and influenced by factors such as age, gender and secretory pattern [51-53]. 
 
1.3.1 Growth 
Somatic growth is, as mentioned above, brought about by a proportional increase in the 
weight and size of several organs. Elongation of the long bones in the body is an 
important step in the longitudinal growth of the body. This is achieved by proliferation 
and hypertrophy of the chondrocytes situated in the epiphyseal growth plates at both 
ends of the bone [54]. In humans, increased levels of estrogen causes apoptosis and 
ossification of the growth plate towards the end of puberty leading to a halt of 
longitudinal growth [55]. 
 
The important role of GH in longitudinal growth is evident from the phenotypes 
produced in genetic and surgical animal models. GHR-/- mice are proportionally smaller 
than wild type mice and exhibit a 50% decrease in body weight [56] and GHRH-/- mice 
reach an adult size of 60% of wild type littermates [57,58]. Analogously, 
hypophysectomized animals also show markedly decreased post-natal growth [59,60].  
 
In 1957, Salmon and Daughaday proposed the somatomedin hypothesis which stated 
that GH does not exert its growth promoting effects directly on target tissues, but 
rather, through an intermediate signaling substance [26]. This unknown substance was 
later dubbed somatomedin [61] and eventually identified as IGF-1 [62]. Circulating 
IGF-1 is primarily produced by the liver in response to GH and is often used as a 
clinical marker for GH secretion since the serum IGF-1 levels are more stable over time 
as compared to GH levels [63,64]. The importance of IGF-1 for longitudinal growth is 
evident from knockout studies in mice; IGF-1-/- mice exhibit a 60% reduction in growth 
compared to wild type littermates [65].  
 
However, the original somatomedin hypothesis has been subject to revision in recent 
years as is has become evident that not all the growth promoting effects of GH are 
mediated by hepatic IGF-1. GH does exert direct effects on muscle, bone and adipose 
tissue and local production of IGF-1 has been shown to be of importance for growth 
[66]. Interestingly, tissue specific hepatic IGF-1-/- mice do not show a growth reduction 
phenotype, but serum levels of IGF-1 are decreased by 75% [67]. Since a large portion 
of serum IGF-1 is bound to IGF binding proteins (IGFBP) that are also produced by the 
liver, it has been suggested that the extrahepatic IGF-1 might be present as free IGF-1 
at a higher rate than hepatic IGF-1, thus allowing for unchanged levels of bioavailable 
IGF-1 [68]. Based on mice knockout experiments where GHR-/- and IGF-1-/- mice were 
crossed it has been estimated that 17% of the postnatal growth rate can be attributed to 
processes unrelated to GH and IGF-1, 35% of the growth is directly associated with 
GH-independent effects of IGF-1 and 14% to IGF-1-independent actions of GH. The 
remaining 34% is dependent on the actions of GH mediated by IGF-1 [66,69]. An 
updated version of the somatomedin hypothesis is depicted in Figure 1.1.  
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Figure 1.1 The updated somatomedin hypothesis. GH promotes systemic production of IGF-1 
by the liver which negatively regulates GH secretion. However, GH also exerts direct effects on 
muscle, bone and adipose tissue. Local production of IGF-1 further mediates GH actions in 
these tissues.  
 
 
1.3.2 Metabolism 
The growth promoting actions of GH also involve complex regulatory action on 
metabolism. GH anabolic actions in muscle and bone involve the stimulation of protein 
synthesis while promoting catabolism of fatty acids instead of glucose. Consequently, 
GH actions leads to hyperglycemia and decreased insulin sensitivity and GH is 
generally considered to have diabetogenic properties [66,70]. Increasing fatty acid 
supply to muscle tissue involves distinct actions in adipose tissue and liver. GH 
promotes lipolysis in adipose tissue and blocks the uptake of fatty acids through 
inhibition of lipoprotein lipase which leads to increased circulating levels of free-fatty 
acids (FFA) and glycerol [53,71,72]. This is highlighted by the GH transgenic mice that 
have decreased body fat but develop severe insulin resistance [73].   
 
In the liver, GH promotes gluconeogenesis and glycogenolysis and reduces the uptake 
of glucose. It also promotes lipogenesis, inhibits lipolysis and increases lipid output by 
the liver [74]. Mice with a liver specific deletion of the GHR exhibit decreased hepatic 
triglyceride secretion, insulin resistance and spontaneous hepatic steatosis [75]. In 
muscle, GH promotes amino acid uptake and protein synthesis without increasing 
proteolysis [76]. Interestingly, muscle specific deletion of GHR seems to protect from 
high-fat diet (HFD) induced insulin resistance. The exact mechanisms behind this 
phenotype are not clear but might be attributable to decreased diabetogenic GH action 
on the muscle [77]. In adipose tissue GH promotes lipolysis and targeted deletion of 
 6 
GHR in fat leads to a doubling of the fat mass, but has no effect on glucose homeostasis 
[78]. GH also seems to play a role in insulin secretion from the β cells in the pancreas. 
Mice with a GHR deletion in the β cells exhibit decreased glucose stimulated insulin 
release and decreased β cell hyperplasia in response to HFD [79].      
 
In contrast to the diabetogenic effects of GH, IGF-1 mimics the actions of insulin and 
promotes glucose uptake, inhibits gluconeogenesis and enhances adipogenesis [80,81]. 
Due to the similarities in somatic effects between IGF-1 and insulin, IGF-1 has even 
been used as an adjuvant therapy to treat diabetes in insulin resistant patients [82]. 
However, IGF-1 has effects distinct from insulin since it increases protein synthesis and 
inhibits proteolysis, while insulin mainly promotes the latter [83]. In summary, IGF-1 
acts as both a mediator of the growth promoting actions of GH and at the same time 
counters its deleterious diabetogenic action. 
 
Another interesting somatic effect of GH is its effect on aging. GHR-/- mice have a 
dramatically increased lifespan, while GH transgenic mice exhibit decreased longevity 
[84]. The GHR-/- mouse has the “world record” in longevity amongst transgenic 
animals and interestingly, humans with GHR mutations (Laron dwarfs) seem to have 
long lifespan too. The effect seems to be independent of IGF-1 actions and is likely 
linked to the perturbations of the carbohydrate metabolism and the reduced oxidative 
stress observed in dwarf mice [85]. 
 
 
1.3.3 Inflammation and immunity 
Besides its actions on postnatal growth and metabolism GH also plays a role in the 
regulation of the immune system. Several different immune cells have been shown to 
express both the GHR, which suggests that GH signaling directly affects immune 
functions, and GH, which implies that paracrine and autocrine hormone secretion might 
play a role in immunity [86]. GH treatment has been shown to promote monocyte 
migration [87] and enhance T cell [88] and B cell development [89].  
 
In mice, transgenic overexpression of bovine GH alters T cell function and decreases 
cytokine production [90]. GHR-/- mice have increased plasma levels of anti-
inflammatory cytokines and decreased levels of proinflammatory cytokines. Since 
inflammatory processes are linked to aging, obesity and insulin resistance it is possible 
that the effects on GH on these somatic processes could be mediated, at least in part, by 
its actions on the immune system and inflammation [91].    
 
GH is able to directly affect cytokine production by immune cells, but the mechanisms 
and effects are unclear. GH have been shown to promote the production of 
proinflammatory cytokines such as Interleukin (IL) -1α, IL-6 and Tumor Necrosis 
Factor α (TNF-α) in immune cells both in vitro [92] and in vivo [93].  In a Finnish 
study, GH treatment of critically ill patients was found to increase both morbidity and 
mortality, likely through modulation of immune function [94], and high levels of GH 
and low levels of IGF-1 are also linked to septic shock and are associated with poor 
outcome [95,96]. However, other studies have found GH treatment both in vivo and in 
vitro to have a reducing effect on proinflammatory cytokine production [97,98]. While 
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it is clear that GH modulates immune functions, the distinct effects and underlying 
mechanisms remain to be elucidated.      
    
 
1.3.4 Pathological conditions associated with GH 
Due to its pleiotropic functions GH is associated with several pathophysiological 
conditions. In humans and animals, deficiencies in the GH axis or in the GH signaling 
pathway lead to dwarfism while excessive amounts of GH lead to gigantism and 
acromegaly. These conditions are characterized by their growth phenotypes but they 
encompass more than altered stature and have provided important insight into the 
metabolic actions of GH.  
  
1.3.4.1 Dwarfism 
There are more than 200 distinct medical conditions that lead to dwarfism and some of 
these affect the GH axis. GH deficiency (GHD) may lead to dwarfism if left untreated 
and can in some cases be related to mutations that affect the secretion and function of 
GH. GHD in children often responds well to GH treatment, and a near normal final 
height is often achieved [99]. 
 
Another cause for dwarfism is Laron Syndrome, which is characterized by insensitivity 
to GH. This condition was first described by Laron et al. in 1966 [100]. Laron 
syndrome is normally caused by mutations in the extracellular domain of the GHR. 
Patients with Laron syndrome have high levels of circulating GH and low IGF-1 levels 
that do not increase in response to GH treatment [101]. These patients can be 
considered the human equivalent of the GHR-/- mouse, which is sometimes referred to 
as the Laron mouse. In line with the physiological traits of the GHR-/- mice, Laron 
syndrome seems to lead to a reduction in pro-aging signaling and protect against 
diabetes and cancer [102]. Clinical treatment of Laron syndrome consists of IGF-1 
therapy before puberty. However, it is not as effective as GH replacement therapy in 
GHD patients. The reason is believed to be the reduced hepatic production of IGFBP 
which leads to a faster clearance of IGF-1 and the fact that the IGF-1 independent 
effects of GH on growth are as of yet unattainable in Laron syndrome patients [103].    
 
1.3.4.2 Acromegaly 
Excessive GH secretion in children leads to accelerated growth and a significant 
increase in height and is referred to as gigantism. If the increase in GH levels occurs or 
persists after the fusing of the epiphyseal plate at puberty, the condition is termed 
acromegaly [104]. The term acromegaly was coined by Pierre Marie who described 
two cases in 1886 [105,106].  
 
The most prevalent cause of acromegaly is excessive GH secretion from pituitary 
adenomas that derive from the somatotropic cells. In some cases increased GH or 
GHRH secretion from tumors in other parts of the body lead to the condition. Common 
visible features are enlargement of the hands and feet, prognathism and macroglossia 
[107]. However, the increased plasma levels of GH seen in these patients also cause 
comorbidities and the patients are at an increased risk for developing diabetes and 
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cardiovascular disease [108]. Again this is in line with the phenotype seen in the GH 
transgenic mice described above.  
 
Treatment for acromegaly is either, surgical removal of the GH or GHRH producing 
tumor, radiation therapy of the tumor, treatment with somatostatin analogues to 
decrease the release of GH, Pegvisomant treatment to antagonize GH action directly or 
a combination of these. Symptomatic treatment of comorbidities may also be called for 
[108].    
 
 
1.4 INTRACELLULAR GROWTH HORMONE SIGNALING 
When GH reaches a target organ it binds to dimerized GHR that span the cellular 
plasma membrane. The two separate binding sites on the GH molecule each interact 
with one GHR protein molecule. Previously, GH was thought to cause receptor 
dimerization [9] but recent studies have shown that the GHR is already present as a 
dimer in the membrane [109] and that GH induces a conformational change in the 
receptor that affects the intracellular part of the GHR and triggers downstream 
signaling [110].   
 
In humans the GHR consist of 620 amino acids and has an approximate size of about 
100 kDa. Following receptor translation the receptor is heavily glycosylated in the 
endoplasmic reticulum and Golgi and its final size when present in the plasma 
membrane increases to around 130 kDa [111-113]. The GHR belongs to the class I 
cytokine receptor family and is closely related to the PRL receptor (PRLR) and the 
erythropoietin receptor [114]. Cytokine receptors are able to initiate signaling through 
several different signaling pathways. Among them, the JAK-STAT pathway is of key 
importance.   
 
 
1.4.1 JAK-STAT Pathway 
The members of the class I cytokine receptor family do not have intrinsic kinase 
activity; instead, each receptor molecule associates with an intracellular tyrosine kinase. 
Four different tyrosine kinases belonging to the same family have been shown to 
associate with cytokine receptors; Janus Kinase (JAK) 1-3 and Tyk2 [115]. The GHR 
was the first receptor of this family to be identified and it is associated with JAK2 
[116]. Upon GH binding to the dimerized GHR the two JAK2 proteins come in close 
proximity of each other and cross-phosphorylate. Following JAK2 cross-
phosphorylation the two kinases phosphorylate the GHR [117]. This promotes the 
binding of the Signal Transducer and Activator of Transcription (STAT) protein to the 
GHR [118]. STATs bind the phosphorylated tyrosines on GHR through its Src 
Homology 2 (SH2) domain [119], and, once bound it in turn becomes phosphorylated 
by JAK2 [120]. Phosphorylated STAT dissociates from the receptor, dimerizes through 
the SH2 domain and migrates into the nucleus of the cell where it acts as a transcription 
factor and initiates the transcription of GH responsive genes [121-123].  
 
A total of seven different STAT proteins have been identified in mammals; STAT1-4, 
STAT5a and b and STAT6 [115]. GHR signaling is primarily mediated by the two 
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STAT5 isoforms; however, studies have shown that GH is also able to trigger 
transcription through STAT1 and STAT3 activation [124,125]. STAT5a and b are 
encoded by separate genes but their amino acid sequence is 96% homologous [126]. 
The divergence between the two isoforms is primarily found in their C-terminal 
transcription activation domains [127] and the two isoforms exhibit differences in their 
transcriptional activity [128]. The downstream effects overlap to a large degree but 
each isoform also has separate effects on transcription [129]. Furthermore, the tissue 
specific distribution varies for the isoforms, for instance STAT5b is the predominant 
isoform in the liver [130,131].     
 
Further clues on the roles of the different STAT proteins come from knockout studies 
in mice. STAT1-/- mice have decreased resistance to viral infections and do not respond 
to interferons (IFN) [132,133]. STAT2-/- mice have a similar phenotype [134], while 
STAT3-/- is embryonic lethal [135]. However, tissue specific knockouts of STAT3 
reveals that it plays an important role in mediating T cell proliferation and anti-
inflammatory signaling in macrophages through IL-2 and IL-10, respectively [136]. 
Disruption of STAT4 and STAT6 causes defects in T cell differentiation; STAT4-/- 
mice have impaired T helper (Th) 1 cell differentiation and STAT6-/- have impaired 
Th2 cell differentiation [137]. Silencing of the two STAT5 isoforms creates distinct 
phenotypes that unveil their respective roles. The generation of STAT5a-/- mice 
revealed the importance of STAT5a for PRL signaling. The knockouts have impaired 
mammary gland development and fail to lactate after parturition [138]. The phenotype 
of the STAT5b-/- mice highlights its importance for GH signaling; postnatal growth is 
reduced in the males and the expression of female predominant genes in the liver is 
upregulated [139]. Disruption of the STAT5b gene feminizes the male mice since it 
abolishes their ability to convert the male specific pulsatile GH secretion into pulsatile 
GHR signaling and the signaling pattern becomes more continuous and similar to the 
secretion pattern seen in females [140]. In humans, inactivating mutations in the 
STAT5b gene cause a syndrome similar to Laron type dwarfism coupled with 
autoimmunity likely due to low levels of T regulatory cells [141]. The condition is rare 
however and so far only seven subjects have been identified [142]. 
 
STAT5b triggers the hepatic expression of several important GH responsive genes 
notably, IGFBP3, IGF-1, SOCS1-3, and CIS [143-145]. STAT5b also induces the 
expression of the transcription factor hepatic nuclear factor 6, which in turn promotes 
further activation of GH responsive genes [146]. It has also been demonstrated that the 
growth promoting actions of STAT5b in the liver are influenced and dependent on the 
glucocorticoid receptor (GR). GR binds to STAT5b and helps promote gene 
transcription and hepatocyte-specific deletion of GR leads to stunted growth [147].   
 
 
1.4.2 Mitogen-Activated Protein Kinase Pathway  
Another well-known pathway that is activated by the GHR is the Mitogen-Activated 
Protein Kinase (MAPK) or extracellular signal-regulated kinase (ERK) pathway [148]. 
The SH2 domain-containing transforming protein (Shc) binds to the phosphorylated 
GHR and is phosphorylated by JAK2. This activates Shc and it in turn, binds to and 
activates the Growth factor receptor bound 2 (Grb2) protein [149]. Grb2 interacts with 
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Sons Of Sevenless (SOS) and this triggers further signaling by the downstream 
signaling proteins Ras, Raf and MEK [150] which leads to the activation of the MAP 
kinases ERK1 and 2 (also known as p44/42) [151,152]. GH activation of MAPK 
signaling is, unlike the STAT signaling triggered by GH, not necessarily dependent on 
JAK2. Deletion of the JAK2 binding site on the GHR leads to a complete abrogation of 
STAT signaling, but the ERK pathway can still be activated [153], likely through GHR 
association to the Src family kinase Lyn [154]. 
 
The activation of the ERK1/2 kinase signaling cascade results in serine phosphorylation 
of STATs [155], activation of ribosomal S6 kinases p90RSK and p70RSK [156,157], and 
activation of phospholipase A2 [158] and the transcription factor c-jun [53]. GH is also 
able to activate other MAPK superfamily members, namely p38 [159] and the c-Jun 
amino terminal Kinase (JNK) [160]. 
 
 
1.4.3 IRS and PI 3-Kinase Pathway 
Canonical activators of the Insulin Receptor Substrates (IRS) are insulin and IGFs. 
However, GH signaling is also able to promote activation of IRS1-3 by JAK2 
phosphorylation [161-163]. Phosphorylation of IRS-1 has been shown to augment and 
amplify GH activation of ERK1/2 [164].  Phosphorylated IRS proteins also constitute a 
binding site for the 85 kDa regulatory subunit (p85) of the Phosphoinositide 3-Kinase 
(PI3K). Activated PI3K phosphorylate phosphatidylinositide (PI) lipids on the 3’ 
position of the inositol ring, and the phosphorylated PIs mediated the downstream 
effects of PI3K [165]. PI3K activation is known to regulate glucose uptake by 
translocation of the glucose transporter type 4 (GLUT4) to the cell membrane [166]. It 
is also involved in DNA synthesis, cell cycle regulation, cell proliferation and 
regulation of apoptosis [167-169].  
 
The activation of the IRS-PI3K pathway by GH, and the subsequent translocation of 
GLUT4, is believed to explain the acute insulin-like effects of GH observed in vitro 
[166,170]. The anti-lipolytic and lipogenic effects of GH are also mediated by PI3K 
activation [163]. In addition to this, GH effects on cell proliferation, metabolism, 
survival and cell cycle regulation have been shown to involve PI3K [165]. 
Interestingly, induction of the p85 regulatory subunit of the PI3K has been proposed to 
explain the anti-insulinic actions of GH [171]. 
 
 
1.4.4 Other Signaling Pathways 
In addition to the pathways described above, GH has been shown to activate several 
other pathways. There is evidence for ample crosstalk between the various signaling 
cascades triggered by GH and the responses to GH are sometimes cell-type and tissue 
specific.  
 
It has been demonstrated that Protein Lipase C (PLC) activity is increased in response 
to GH and PLC-γ has been shown to be interact with GHR and JAK2 and become 
phosphorylated in response to GH. PLC hydrolyses phosphatidylinositol 4,5-
bisphosphate which produces two second messenger molecules; diacylglycerol (DAG) 
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and inositol trisphosphate (IP3). DAG interacts with and activates Protein Kinase C 
(PKC) while IP3 transiently increases free Ca2+ concentration in the cell. The increase 
in Ca2+ also serves to activate PKC. PLC/PKC mediated GH actions include activation 
of the ERK1/2 pathway [172], chemotaxis [173], induction of c-fos expression [174] 
and increasing intracellular Ca2+ concentrations [175].  
 
The Focal Adhesion Kinase (FAK), which is primarily involved in integrin signaling 
[176], can be phosphorylated in response to GH in a JAK2 dependent fashion [177]. 
FAK is also involved in the regulation of cell motility and morphology [178] and it has 
been suggested that GH effects on actin rearrangement and chemotaxis might be 
mediated by FAK [165] in a process that requires p38 MAPK activation [159].   
 
GH has also been reported to activate Nuclear Factor-κB (NFκB) and that this might in 
part be dependent on PI3K activation of Akt [179]. GH initiated NFκB activation in 
chondrocytes has been shown to be of importance for chondrogenesis and metatarsal 
growth and dependent on STAT5b [180]. The effects of GH on cytokine production in 
immune cells also seem to be mediated by NFκB activation [181].   
 
The SH2-domain containing protein SH2Bβ is another regulator of GH signaling 
events. SH2Bβ augments the activity of JAK2 and increase its kinase activity in 
response to GH [182].  
 
Figure 1.2 Signaling pathways activated by GH and the negative regulation of GH signaling. 
GH signals mainly through the JAK-STAT pathway but can also activate IRS-PI3K and MAPK 
signaling among others. The negative regulation of GHR signaling involves dephosphorylation 
by phosphatases, inhibition of JAK and endocytosis and degradation of GHR. Abbreviations are 
explained in the text.    
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1.5 NEGATIVE REGULATION OF GH SIGNALING 
As mentioned earlier, intracellular signaling cascades need to be regulated to ensure 
adequate responses and avoid unintended outcomes. Besides the regulation of GH 
secretion described above, intracellular GH signaling is regulated by a number of 
different factors that influence the actions it elicits.  
 
  
1.5.1 Protein Inhibitors of Activated STATs 
One way by which the JAK-STAT pathway can be suppressed is by the Protein 
Inhibitor of Activated STATs (PIAS) family of proteins. PIAS proteins bind to 
activated dimerized STATs and prevent them from binding to DNA and initiating the 
expression of their target genes. PIAS proteins also exhibit E3 ligase activity and are 
able to modify other proteins by covalently attaching the Small Ubiquitin-like Modifier 
protein (SUMO) to them [183]. While PIAS proteins were originally discovered as 
STAT inhibitors it has become clear that they can repress and modify the actions of 
several other transcription factors, for instance p53 [184] and NFκB [185]. PIAS1 is 
known to inhibit STAT1 while PIAS3 has been shown to inhibit STAT3 and STAT5. 
PIASx and PIASy are known to interact with STAT4 and STAT1, respectively, but 
their functional mechanism remains to be elucidated [186]. PIAS inhibition of STATs 
does not require SUMOylation of the STAT-proteins but the E3 ligase activity may 
matter in some instances, suggesting that the inhibition might involve the 
SUMOylation of other targets [183].  
 
The expression of PIAS proteins is constitutive and it has been suggested that PIAS 
proteins act in a buffering capacity by maintaining the concentration of activated 
STATs at a certain level [186]. Furthermore, there is no evidence that PIAS proteins 
influence GH signaling directly but given their role in the regulation of STAT mediated 
transcription it cannot be excluded that they have an impact on the actions of GH.    
 
 
1.5.2 Phosphatases 
GH signaling propagation is mainly achieved by phosphorylation of signaling proteins. 
Dephosphorylation by phosphatases is another method by which GH signaling is 
negatively regulated. GHR is dephosphorylated by the protein tyrosine phosphatases 
(PTP), PTP1B and PTPH1. Two additional PTPs have been implicated in the regulation 
of GHR phosphorylation, TC-PTP and SAP1, but it remains to be elucidated if these 
two really do dephosphorylate the GHR in vivo [187,188]. PTP1B-/- mice exhibit 
increased STAT5b and JAK2 phosphorylation in response to GH [188] and it has been 
demonstrated that PLCγ1 is required for the negative regulation of GH signaling by 
PTP1B since it acts as a bridge between PTP1B and JAK2 and brings the two proteins 
into close proximity of one another [189].  
 
Another class of phosphatases that regulate GH signaling is the SH2 domain-containing 
PTPs (SHP), SHP1 and SHP2. GH is able to activate SHP1, which enables the 
phosphatase to bind to and dephosphorylate JAK2 [190]. SHP1 has also been shown to 
interact with STAT5 and decrease its activity [191]. Deletion of SHP1 leads to an 
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increased duration of JAK2 and STAT5b phosphorylation and demonstrates its role as 
a negative regulator of GH signaling [190]. For the related SHP2 on the other hand, 
both inhibiting and signaling promoting activity has been demonstrated. SHP2 interacts 
with GHR, JAK2 and signal-regulatory protein (SIRP) α and GH stimulation leads to 
SHP2 phosphorylation and induces interaction with Grb2. Over-expression of 
catalytically inactive SHP-2 leads to decreased GH-induced gene expression suggesting 
that it is a positive regulator of GH signals [192]. SHP2 has been shown to interact with 
phosphorylated tyrosine 595 and tyrosine 487 on the GHR and mutation of these 
residues leads to an increase in GH signaling duration suggesting that SHP2 might act 
as a negative regulator of GH signaling [193]. It is worth noting that other negative 
regulators of GH signaling also interact with these residues and that the effect seen 
might be attributable to their activity rather than that of SHP2 [194,195].  
 
SHP2’s interaction partner SIRPα is also known to negatively regulate GH signaling. 
SIRPα is a transmembrane glycoprotein that becomes phosphorylated in response to 
GH. Phosphorylated SIRPα inhibits GH induced JAK2, STAT5 and ERK 
phosphorylation but the mechanism for its actions is unclear [196,197].         
 
 
1.5.3 GHR endocytosis  
The availability of GHR in the membrane of a target cell naturally influences 
downstream signaling. Absence of receptors renders a cell resistant to the actions of 
GH while an abundance of receptors sets the stage for a substantial downstream 
signaling cascade. As mentioned previously, the GHR is present as a homodimer in the 
cell membrane where it either binds to GH or is proteolytically cleaved to create 
GHBP. Both cleaved and intact receptors are endocytosed via clathrin-coated pits in the 
membrane [198], and possibly by the caveolae [199], although this is a subject of 
debate [200]. GHR internalization is constitutive [201], however, GH stimulation is 
known to amplify the process [202]. Once internalized, the GHR is degraded at either 
the lysosome or the proteasome [196].  
 
Extensive studies in Chinese hamster ovary cells by Strous et al. have provided a lot of 
insight into the mechanisms of GHR internalization and processing. Internalization of 
the GHR requires a functional ubiquitin-proteasome system, but does not require 
ubiquitination of the receptor itself [200]. GHR internalization depends on two small 
motifs located in the juxtamembranous region of the intracellular part of the GHR: the 
ubiquitin-dependent endocytosis (UbE) motif (DSWVEFIELD), which is required for 
endocytosis under both induced and basal conditions, and a small degron motif 
(DSGRTS), which contributes to endocytosis under basal conditions [203]. Mutation of 
the phenylalanine in the UbE motif effectively blocks GHR internalization and 
prolongs GH signaling [204]. It has been shown that the WD40 domain of the ubiquitin 
ligase β-Transducin repeat-Containing Protein (βTrCP) interacts with the UbE and 
degron motifs and promotes the endocytosis and ubiquitination of the GHR [203,205].  
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1.5.4 SOCS proteins 
An important family of negative regulators of hormone, cytokine and growth factor 
signaling are the SOCS proteins. The SOCS family contains 8 members; Cytokine-
Inducible SH2-containing protein (CIS) and SOCS1-7. SOCS proteins are 
characterized by a C-terminal SOCS-box, a central SH2 domain and an N-terminal 
domain of variable size; SOCS1 and 3 also contain a Kinase Inhibitory Region (KIR) 
situated in the N-terminus [206]. Their domain organization is summarized below in 
Figure 1.5. 
 
Four of the SOCS-family members have been implicated in the regulation of GHR 
signaling: SOCS1-3 and CIS [207]. They act in a negative feedback loop, where GH 
triggers their expression and once translated into proteins they terminate the signal. The 
kinetics for the expression differs somewhat, with an immediate, transient induction of 
SOCS1 and 3 and a slower increase of CIS and SOCS2 expression following GH 
stimulation [208,209]. Different mechanisms for the actions of SOCS proteins have 
been elucidated: they can directly inhibit kinase activity by the KIR domain (SOCS1 
and 3), compete with other signaling molecules for binding to phosphorylated tyrosines 
and act as ubiquitin ligases that mediate the proteasomal degradation of their targets 
[210]. The actions of SOCS proteins will be described in greater detail in the following 
chapters but it is interesting to note that SOCS2-/- mice display increased GH sensitivity 
and growth.   
 
 
1.6 THE UBIQUITIN-PROTEASOME SYSTEM 
In 2004, Aaron Ciechanover, Avram Hershko and Irwin Rose were awarded the Nobel 
Prize in Chemistry for the discovery of ubiquitin mediated protein degradation. In the 
late 1970’s they discovered how covalent attachment of a small polypeptide to other 
proteins mediated their degradation [211]. The small polypeptide they identified was 
eventually named ubiquitin (Ub). Since the initial discovery several structurally similar 
proteins that are also used as post-translational modifications have been described. Of 
note are the SUMO proteins [212] and the Neural precursor cell-Expressed 
Developmentally Downregulated (NEDD8) protein [213]. The field of ubiquitin 
research has expanded significantly and ubiquitin is now known to have other effects 
besides degradation and to affect a multitude of biological processes. For instance, 
therapies that block the system are employed clinically to influence the growth of 
cancer cells [214].  
 
The ubiquitin protein consists of 76 amino acids of which 7 are lysines [215,216]. The 
process of ubiquitination is the covalent attachment of the C-terminal end of ubiquitin, 
on usually a free lysine, on a target protein [216]. The process requires three enzymes: 
an ubiquitin activating enzyme (E1), an ubiquitin conjugating enzyme (E2) and an 
ubiquitin ligase enzyme (E3). First, the C-terminus of ubiquitin is covalently bound by 
a thioester linkage to a serine on the E1 in an ATP dependent reaction. Next, the 
ubiquitin moiety is transferred to a serine on the E2. In the final part of the process, the 
E2 interacts with the E3 which in turns interacts with the target protein. The ubiquitin is 
transferred from the E2 and linked through an isopeptide bond to a lysine on the target 
protein (sometimes via the E3) [217].   Figure 1.3 schematically depicts this process.   
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Figure 1.3 The Enzymatic Process of Ubiquitination by RING Ligases. 1. E1 activating enzyme 
covalently binds ubiquitin on a free serine in an ATP driven reaction. 2. Ubiquitin is transferred 
from E1 to a serine on the E2 conjugating enzyme. 3. The E2 interacts with the E3 ubiquitin 
ligase and transfers ubiquitin to a free lysine on the target protein bound to the E3. The 
process may end after the addition of a single ubiquitin but may also be repeated to generate 
polyubiquitin chains.  
 
Once a first ubiquitin moiety has been attached to a target protein, several more can be 
attached to lysines or the N-terminal amine group of the preceding ubiquitin. One 
ubiquitin molecule can have more than one lysine occupied by other ubiquitin moieties, 
leading to branched chains. The lysine used for formation of the polyubiquitin chain 
determines the outcome of the ubiquitination [218]. The two most well characterized 
chains are Lys48-linked and Lys63-linked chains [219]. The generation of Lys48-
linked polyubiquitin chains on a target protein leads to its degradation by the 26S 
proteasome [220]. The 26S proteasome consists of a central 20S core subunit, which 
harbors the proteolytic activity of the complex, and two or more 19S subunits that bind 
to polyubiquitinated targets, deubiquitinates and denatures them and ultimately feeds 
them into the catalytically active core where they are degraded [221]. Lys63-linked 
chains primarily play a role in the DNA damage response and in kinase activation. 
Generation of Lys63-linked chains creates a binding surface for proteins that contain 
Ubiquitin Binding Domains (UBD) and it can thus promote interactions that are 
required for signaling propagation [222]. Pathways that involve Lys63-
polyubiquitination include IL-1, Toll-like Receptor (TLR) and TNF-α signaling and 
Lys63 chains have been demonstrated to be involved in NFκB activation [223,224]. 
The roles of other types of ubiquitin chains are less well elucidated; some are also 
involved in proteasomal degradation and involvement in mitochondrial function, cell 
cycle regulation, endocytosis, nuclear translocation and cell signaling cascades have 
been demonstrated [219].    
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In humans, 8 different E1 enzymes have been described. Two of them activate 
ubiquitin and the remaining six activate other ubiquitin-like proteins (UBL), (SUMO 
and NEDD8 for instance) [225]. The E2 enzymes are more diverse and so far 35 
distinct ones have been identified in humans [226], again, some of them conjugate 
ubiquitin and some of them UBLs. The E3 ligases are responsible for providing the 
specificity to the system since they interact directly with the target protein, and 
functional genomic annotation suggests that there may be up to 600 different E3 ligases 
in humans [227]. While the target recognition domains of E3 ligases vary greatly there 
are well conserved structural domains that mediate the interaction with E2 enzymes and 
ubiquitin. Two distinct families have been identified; the Homologous to the E6-
AP Carboxyl Terminus (HECT) domain family [228] and the Really Interesting New 
Gene (RING) finger domain family [229] (including the related PHD finger and U-box 
containing proteins) [230,231]. The two families differ structurally as well as 
mechanistically since RING finger containing proteins only associate with the E2 and 
the E2 directly transfers the ubiquitin to the target protein while the HECT domain is 
capable of forming a covalent intermediate with ubiquitin [232,233]. E3 ligases based 
on single peptide chains do exist but many E3 ligases are complexes of several proteins 
that contribute to different aspects of their activity [234].  
 
 
1.6.1 Cullin-RING ligases 
The GH signal-regulating ubiquitin ligases mentioned above, βTrCP and SOCS 
proteins, belong to a large sub-family of E3 ligases known as Cullin-RING ligases 
(CRL) [235,236]. They form multimeric complexes which involve a family of proteins 
known as Cullins (Cul). The Cullin family contains seven proteins, Cullin1-3, 4A and 
B, 5 and 7, and they act as a scaffold that links RING-box (Rbx) proteins to the target 
recognition part of the E3 ligase [237,238].  
 
The RING domain is crucial for the interaction with the E2 and for certain RING 
domain containing proteins it seems that the affinity for ubiquitin-bound E2s is 
increased in comparison to free E2s [239]. The detailed mechanism of how RING 
domains mediate the transfer of ubiquitin to target proteins has remained elusive but 
recent publications have shown that ubiquitin can fold back and form non-covalent 
bonds with both the E2 and the RING domain. The current hypothesis is that this serves 
to stabilize ubiquitin during the transition state before it is bound to a free amine on the 
target protein [240,241].      
 
The highly conserved C-terminus of the Cullins is responsible for the interaction with 
Rbx [242]. The N-terminal ends of the Cullin proteins are more variable and they 
interact with distinct motifs present in the substrate recognizing part of the CRL. Cul1 
and Cul7 interact with S-phase-Kinase-associated Protein-1 (Skp1) which is bound to 
an F-box containing protein that contains a substrate interacting motif of some kind 
[243,244]. Cul1 containing CRLs are usually referred to as Skp-Cullin-F-box (SCF) 
complexes, and βTrCP constitutes an example of an F-box protein that participates in 
SCF complex formation [235,245]. Cul2 and Cul5 interact with SOCS-box containing 
proteins that interact with Elongin B and C; SOCS proteins exemplify this class of 
CRLs [236]. Cul3 interacts with proteins that contain Broad complex, Tramtrack, Bric-
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a-brac (BTB) domains [246] while Cul4 is believed to interact with the adaptor DNA-
Damage-Binding protein-1 (DDB1) [247].  
 
Cullin proteins do not just constitute a passive scaffold for the binding of the other 
components of the ubiquitination reaction. It has been demonstrated that Cullins can be 
activated by C-terminal neddylation by the NEDD8 E2, Ubc12 [248,249], and the E3, 
Defective in Cullin Neddylation (DCN1) [250], in collaboration with the Cullin-bound 
Rbx protein [251]. Cullin neddylation greatly increases the enzymatic activity of CRLs 
for a number of substrates [252]. Attachment of NEDD8 induces a conformational 
change that brings the two ends of the Cullin molecule closer. This allows the Rbx-
bound E2 to come in direct contact with the substrate and facilitates the transfer of 
ubiquitin moieties [253,254]. NEDD8 might also serve as a co-factor for the binding of 
the E2 to the CRL [252]. Another feature of Cullin activity is dimerization, which is 
promoted by the N-terminus. Dimerization does not seem to be a complete necessity 
for CRL activity but it might be important for proper elongation of ubiquitin chains 
[255].  
 
Figure 1.4 Putative mechanism for ubiquitin transfer by Cullin-RING ligases. Cullin interacts 
with the target recognizing (TR) part of the E3 ligase via the SOCS-box/F-box/BTB domain 
(S/F/B). Neddylation of Cullin induces a conformational change and promotes the binding of 
E2-Ub to Rbx (1). Ub is folded in and interacts with the E2, Rbx and Cullin (2). This interaction 
stabilizes Ub during the transfer to the target (3). The sequence of events might vary.  
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Two important regulators of Cullin activation are the Cop9 Signalosome and Cullin-
Associated and Neddylation-Dissociated 1 (CAND1) protein. The Cop9 Signalosome 
deneddylates Cullins and can thus be seen as a negative regulator of CRL activity 
[256]. Similarly, CAND1 is capable of binding to un-neddylated Cul1 and blocking 
both the Skp1 and the NEDD8 binding sites. It is however not able to bind to 
neddylated Cul1 due to the conformational change induced by the neddylation and 
CAND1 has been shown to negatively regulate CRL activity in vitro [257]. However, 
elimination of CAND1 or the Cop9 Signalosome in vivo does not increase the activity 
of CRLs, rather it attenuates the activity [255,258]. This suggests that their roles are 
more complex than originally expected. It is possible that de-neddylation and re-
neddylation of Cullins might be required for proper activity of CRLs and to avoid auto-
ubiquitination [255]. Recent reports suggest that CAND1 promotes the assembly of 
new SCF complexes by triggering the exchange of F-box proteins [259].  
 
 
1.6.1.1 SOCS-box proteins 
An interesting group of CRLs are the SOCS-box family of proteins, also referred to as 
Elongin C-Cullin-SOCS-box (ECS) complexes. The family is believed to encompass 
up to 80 proteins in humans based on the genomic occurrence of C-terminal SOCS-
boxes [260]. ECS complexes consist of a SOCS-box containing protein (with some 
form of substrate interacting domain) binding to Elongin B and Elongin C with the 
SOCS-box. The N-terminus of Cul2/5 interacts with both Elongin C and the SOCS-box 
and it has been shown that sequence variations within the SOCS-box correlate to Cul2 
or Cul5 preferential binding [236]. The Elongin B/C-SOCS-box is structurally 
homologous to the Skp1-F-box structure, indicating that it is a well conserved Cullin 
interacting conformation [261,262]. The interaction between the SOCS-box and 
Elongin B/C has been shown to stabilize the ECS complex while disrupting mutations 
or deletion of the SOCS-box eradicates the E3 ligase activity for several different ECS 
complexes [194,263-268]. The various substrate interacting domains of ECS 
complexes include SH2-domains, Ankyrin repeats, Leucine-Rich Repeats (LRR), 
WD40-domains and SPlA and Ryanodine receptor (SPRY)-domains [260]. 
 
Notable examples of SOCS-box proteins are the SOCS family, the von Hippel-Lindau 
tumor suppressor protein (VHL), and the Ankyrin repeat SOCS-box proteins (ASB). 
VHL was the first SOCS-box protein to be characterized as an Elongin B/C binding E3 
ligase [269,270]. VHL targets the Hypoxia Inducible Factor (Hif) 1α for proteasomal 
degradation and plays an important role in the regulation of angiogenesis. Mutations in 
the vhl gene that affect the actions of the encoded protein lead to von Hippel-Lindau 
disease which is characterized by a predisposition for tumor growth [271]. The ASB 
family consist of 18 proteins, and although less explored than VHL and SOCS proteins, 
they are important regulators of tumor invasion [272], cell differentiation and protein 
synthesis [273], arteriogenesis [274] and spermatogenesis [275].  
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1.6.2 TLR signaling and ubiquitination 
The production and release of cytokines is regulated by a myriad of signaling pathways. 
One interesting family of receptors that control cytokine production in response to 
invading pathogens is the Toll-like receptor family. TLRs recognize conserved 
molecular motifs known as pathogen-associated molecular patterns (PAMP). Examples 
of PAMPs include microbial nucleic acids, parts of bacterial cell walls, lipoproteins and 
Lipopolysaccharides (LPS) [276]. TLRs are present on either cell surfaces or 
intracellularly depending on what type of PAMP they are activated by. Here, the 
signaling of TLR4 will be described.    
 
TLR4 is activated by LPS which is found in the outer membrane of Gram-negative 
bacteria, but it can also be activated by host-derived molecules, for instance low-
density lipoproteins which may contribute to the development of chronic inflammation 
associated with atherosclerosis and type 2 diabetes [277,278]. Ligand binding to TLR4 
recruits the adaptor proteins Myeloid Differentiation factor 88 (MyD88) and MyD88 
adaptor-like protein (Mal) to the receptor. They in turn bind IL-1 Receptor Associated 
Kinases (IRAK) 1 and 4 that become activated upon phosphorylation. Activated IRAKs 
will interact with TNF Receptor Associated Factor (TRAF) 6 which will associate with 
and activate TGF-β Activated Kinase (TAK) 1. Here the pathway bifurcates as TAK1 
will initiate both MAPK signaling and the activation of NFκB. In addition to the 
canonical MyD88-pathway, TLR4 can also signal through the TRIF-dependent 
pathway (Toll/IL-1 receptor domain-containing adaptor inducing IFN-β) which 
involves signaling through TRAF3 and ultimately leads to interferon production 
through activation Interferon Regulatory Factor (IRF) 3 [279].  
 
Ubiquitination plays a pivotal role in both the regulation and mediation of signaling in 
this pathway. TRAF6 is an E3 ligase and will polyubiquitinate target proteins, 
including itself, with Lys63-linked chains. The TAK1 binding proteins (TAB) 2 and 3 
bind to Lys63-polyubiquitin chains and associate with TRAF6, which leads to the 
activation of TAK1 [279,280]. The TRAF6-generated Lys63-chains can be recognized 
by the ubiquitin-binding domain of the regulatory subunit of the Inhibitor of NFκB 
(IκB) kinase (IKK) complex. This allows TAK1 mediated phosphorylation and 
activation of the complex [281]. The IKK complex goes on to phosphorylate IκB, 
which allows it to be targeted for ubiquitin-dependent proteasomal degradation by 
βTrCP. Degradation of IκB exposes the nuclear translocation signal of NFκB and 
allows it to enter the nucleus and initiate gene transcription [282]. An interesting family 
of E3 RING-ligases that also affect TLR and NFκB signaling is the Inhibitors of 
Apoptosis Proteins (IAP). Several proteins in this family contain an ubiquitin binding 
domain that allows them to interact with already ubiquitinated proteins and one of the 
more well-studied members, XIAP, has been shown to promote the interaction between 
TAK1 and IKK through interaction with TAB1 and thus positively affect signaling 
[283,284]. Two other members of the family, cIAP1 and 2 interact with MyD88 and 
promotes K48-linked ubiquitination of TRAF3 which has a positive effect on MAPK 
signaling [276]. Negative ubiquitin related regulation of TLR signaling include 
deubiquitination of TRAF6 by A20, ubiquitination and proteasomal degradation of 
TLR4 by Triad3A and K48-linked Mal ubiquitination by SOCS1 [280].     
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1.7 BIOLOGICAL EFFECTS AND FUNCTIONS OF SOCS PROTEINS 
The SOCS proteins were, as the name implies, originally identified as negative 
regulators of cytokine signaling. They are, as mentioned above, primarily associated 
with regulating the JAK-STAT pathway which is employed by several of the cytokine 
family receptors. Since the expression of SOCS proteins is chiefly triggered by STAT 
signaling they tend to act in a negative feedback loop by downregulating the very 
pathway that triggers their activation. However, SOCS actions are not limited to the 
JAK-STAT system and the role of SOCS proteins is not solely that of feedback 
inhibition. For a summary of factors that induce SOCS expression, pathways regulated 
by SOCS, and proteins targeted for ubiquitination by SOCS proteins please refer to 
Table 1.1.  
 
 
 
Figure 1.5 Domain structure of the SOCS family. All SOCS proteins contain a C-terminal SOCS-
box, a central SH2 domain and an N-terminal domain of varying length. SOCS1 and 3 both 
have a KIR domain in the N-terminus. Domain sizes are approximate.   
 
 
1.7.1 SOCS1 and SOCS3 
The two most investigated members of the SOCS family are SOCS1 and 3. They have 
primarily been implicated in the regulation of cytokine signaling in relation to 
immunological functions but also affect hormone signaling and metabolism. SOCS1-/- 
mice exhibit stunted growth, liver degeneration and underdeveloped immune responses 
and they die within 3 weeks of birth [285]. The phenotype can be reverted if the IFN-γ 
gene is knocked out simultaneously, underscoring the importance of SOCS1 for the 
regulation of IFN signaling [286]. Deletion of SOCS3 leads to an embryonic lethal 
phenotype due to functional defects of the placenta [287]. Conditional SOCS3 deletion 
models have revealed a role for SOCS3 in hematopoiesis and the regulation of 
Granulocyte-Colony Stimulating Factor (G-CSF) and IL-6 signaling [288,289]. SOCS1 
and 3 also negatively regulate insulin signaling by mediating the degradation of IRS-1 
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and 2 [290]. Interestingly, muscle specific deletion of SOCS3 improves HFD induced 
insulin signaling [291] while liver specific deletion does not and instead promotes 
lipogenesis, possibly due to altered leptin sensitivity [292].  
 
Ubiquitin ligase activity has been demonstrated for both SOCS1 [293] and 3 [290,294]. 
However, due to the presence of the KIR domain and their ability to directly inhibit 
kinases, ubiquitin ligase activity is not crucial for their regulation of cytokine signaling. 
Deletion of the SOCS-box in SOCS1 and 3 in vivo ameliorates the phenotypes 
observed for the complete knockouts, but does not completely restore the animals 
[267,295]. Furthermore, mice can be rescued from LPS-induced septic shock by the 
injection of cell penetrating recombinant SOCS3; an effect likely mediated by the KIR 
domain [296]. Taken together, this demonstrates the importance of the KIR domain for 
the in vivo actions of SOCS1 and 3.  
 
 
1.7.2 SOCS 4, 5, 6 and 7  
The latest additions to the SOCS family are also its largest members [297]. 
Specifically, the N-terminal domain of SOCS4-7 is significantly larger than that of the 
other SOCS family members. However, less is known about the actions of this part of 
the family. SOCS5-/- mice have no distinctive phenotype [298], while SOCS6-/- mice 
exhibit slight growth retardation [299]. SOCS7-/- mice are also slightly smaller than 
wildtype littermates and they suffer from hydrocephalus but have enhanced insulin 
signaling, likely due to an increase in β-cell mass [300,301]. SOCS4 and 5 have 
primarily been linked to the regulation of the epidermal growth factor receptor [302]. 
SOCS6 has a positive effect on insulin signaling, and might have cancer suppressing 
effects through its regulation of c-Kit receptor signaling [303,304]. SOCS7 on the other 
hand seems to negatively influence insulin signaling but is a positive marker for breast 
cancer [300,305]. 
  
 
1.7.3 CIS 
The cytokine inducible SH2-containing protein was the first SOCS family member to 
be described and it is the one most closely related to SOCS2 [306]. It is one of the 
smaller members of the family and it lacks the KIR domain present in SOCS1 and 3. 
CIS-/- mice show no obvious phenotype, but transgenic CIS mice exhibit slight growth 
retardation [307,308]. The actions of CIS overlap with the actions of SOCS2 to a large 
degree and they likely compete for the same binding sites on the GHR [119]. Besides 
regulation of GH and PRL signaling [309], CIS also regulates other cytokine signals 
[306] and is important for the maturation and differentiation of T cells [310] and 
Natural Killer (NK) cells [307]. CIS can attenuate STAT5 signaling by competing for 
the same binding sites with its SH2 domain and CIS mediated ubiquitination of the 
apoptosis triggering Bcl-2-interacting mediator of cell death (Bim) protein has been 
demonstrated [311,312].    
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1.7.4 SOCS2 
The simultaneous discovery of SOCS1, 2 and 3 was reported by Starr et al in 1997. In 
line with previous publications on CIS, they were identified as negative feedback 
regulators of cytokine signaling [313]. The four (at the time described) members were 
soon identified to be GH regulated and SOCS2 and CIS were found to be reduced in 
hypophysectomized animals [208,314]. Once knockout animals were generated the 
paramount importance of SOCS2 for the regulation of longitudinal growth became 
apparent. SOCS2-/- mice exhibit excessive growth that commences 3 weeks after birth. 
The males are approximately 40% heavier and the females 20% heavier than wildtype 
littermates. The weight increase in these animals is not due to any general increase in 
adiposity, but to a proportional increase in body size. The animals are lean and have 
perturbed GH signaling. There is no increase in systemic IGF-1 levels but local 
expression is increased in several organs [315]. Dual-knockout of SOCS2 and 
STAT5b, and crossing of SOCS2-/- mice with GHRH signaling deficient mice 
abolished the original phenotype and confirmed that the increased growth observed in 
SOCS2-/- mice is due to increased sensitivity to GH [195,316]. In humans, SNPs in the 
vicinity of the SOCS2 gene are associated with stature [317-319]. The SOCS2 gene 
contains a GH responsive element and its expression is directly regulated by STAT5 
[320]. While this is true for several of the other members of the SOCS family, none of 
the knockout or transgenic models have such a profound effect on postnatal growth as 
SOCS2. Interestingly, SOCS2 transgenic mice also exhibit enhanced growth and in 
vitro experiments have shown that the inhibitory effect on GH signaling is seen at low 
levels of SOCS2, while increased levels seem to have a signaling enhancing effect 
[195,321]. It has been suggested that this might be caused by SOCS2 mediated 
inhibition of other SOCS proteins, and it has been demonstrated that SOCS2 can 
counter the inhibitory effects of SOCS1 and 3 [314,322,323]. Similar to CIS, SOCS2 
also lacks the KIR domain and thus utilizes other mechanisms for its inhibitory actions. 
Both competitive inhibition and ubiquitin ligase activity have been suggested; and 
SOCS2 has been demonstrated to target both the Proline-rich tyrosine Kinase 2 (Pyk2) 
and GHR for proteasomal degradation [324] (Paper I, [194]). Several factors can induce 
the expression of SOCS2, either through STAT5, or through independent mechanisms, 
and thus attenuate GH signaling [313,325].  
 
Besides its actions on GH signaling SOCS2 has been implemented in the regulation of 
other cytokines (Table 1.1) and immune cell regulation. SOCS2-/- mice are more 
susceptible to infection and exhibit increased levels of proinflammatory cytokines in 
response to certain pathogens. Also, expression of SOCS2 is induced by lipoxins and 
has been demonstrated to mediate some of their anti-inflammatory actions [326]. The 
role of SOCS2 in the differentiation and maturation of immune cells has come into 
focus as of late. The proinflammatory, M1 macrophage population is enriched in 
SOCS2-/- mice. LPS treatment leads to even further enrichment and SOCS2-/- mice are 
highly susceptible to LPS induced septic shock. Interestingly, macrophage-specific 
deletion of SOCS3 in mice leads to a diametrically different phenotype and skews the 
macrophage population towards an anti-inflammatory, M2 polarization which protects 
the animals from the deleterious effects of LPS [327]. This is in stark contrast to the 
finding that recombinant SOCS3 can be used to rescue mice from LPS treatment, but 
might be contributed to increased levels of SOCS1 in SOCS3-ablated macrophages.  
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SOCS1-/- mice are also highly sensitive to LPS and SOCS1 has been shown to inhibit 
TLR4 signaling in macrophages [328]. Another example of the effect of SOCS proteins 
on differentiation is their role in Th cell polarization. Deletion of SOCS2 in mice leads 
to an increased Th2 population [329], while deletion of SOCS1 increase Th1 
differentiation and removal of SOCS3 promotes Th1 and Th17 generation [330]. 
SOCS2 is also implicated in TLR-ligand induced Dendritic Cell (DC) maturation and 
activation; however, the effects observed by different studies are contradictory 
[331,332]. Similarly, SOCS2 has been described as both a negative and a positive 
regulator of TLR signaling and the exact mechanisms remain to be elucidated 
[331,333]. 
 
While the SOCS2-/- mice do not display any obvious metabolic phenotype, SOCS2 has 
been linked to metabolism and diabetes. Overexpression of SOCS2 in the β cells of the 
pancreas leads to diminished insulin secretion and hyperglycemia [334]. In humans, 
SNPs in the SOCS2 gene have been linked to an increased risk of developing diabetes 
[335]. Our own studies have also revealed that deletion of SOCS2 protects against 
hepatic steatosis but worsens insulin sensitivity in mice challenged with a HFD (Paper 
III, [336]). In addition, previous work has shown that SOCS2 deficiency induces 
changes in hepatic gene expression that only partially overlap with known GH induced 
effects, suggesting that not all of the effects attributed to SOCS2 are GH dependent 
[337]. Further processes affected by SOCS2 include mammary gland development 
[338], neural differentiation [339], bone mineral density [340] and allergic responses 
[329].  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For detailed references for the factors listed in Table 1.1 please refer to the following 
publications: [210,260,302,303,311,341-346].  
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2 AIMS 
The general goal of the work presented in this thesis was to determine the mechanism 
of action for SOCS2 and to investigate its physiological role in the regulation of 
metabolism. The following aims were therefore set: 
 
1. To determine the molecular mechanism whereby SOCS2 regulates GH 
signaling. (Paper I). 
 
2. To evaluate the importance of the individual domains in relation to SOCS2 
function (Paper I and II). 
 
3. To determine what role SOCS2 plays in hepatic metabolism and the 
development of insulin resistance and type 2 diabetes (Paper III). 
 
4. To investigate the possibility of interfering with SOCS2 functions with 
interfering compounds (Supplemental data). 
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3 METHODS 
To achieve the goal of understanding SOCS2 mechanism and actions several different 
methods were employed. Below follows a brief summary of methods of note, for a 
more detailed description please refer to the individual papers.  
 
3.1 ANIMAL AND CELLULAR MODELS 
For this study several model systems were used to study cell signaling, protein function 
and metabolic effects. The animal and cellular models used are described below. 
  
3.1.1 Mice 
Our animal studies were performed with SOCS2-/- mice (Paper I and III) [315]. They 
derive from the C57BL/6J strain and wildtype C57BL/6J mice were used as controls. 
Animal experiments were carried out both at the Department of Microbiology, Tumor 
and Cell Biology at Karolinska Institutet, Sweden, and at the University of Las Palmas 
de Gran Canaria, Spain. All animal experiments were carried out in accordance with 
law and local regulations and in compliance with the respective Animal Ethics 
Committees. Ethical permits were obtained as required. To induce obesity and insulin 
resistance the mice were fed a HFD ad libitum for 2 or 4 months; controls were fed a 
normal chow diet (Paper III).   
 
3.1.2 Cells 
3.1.2.1 Cell lines 
All cells were obtained from the American Type Culture Collection. Before stimulation 
with GH cells were washed and incubated for at least 4 hours in media lacking Fetal 
Bovine Serum (FBS).  
 
HEK293T cells were used to study the effects of wildtype and mutant version of SOCS 
on the GHR (Paper I, II and Supplemental data). HEK293T cells were cultured in 
DMEM supplemented with 10% FBS and 100 U/ml penicillin and 100 µg/ml 
streptomycin at 37°C, 5% CO2. SuperFect (Qiagen) was employed according to the 
manufacturer’s protocol to carry out transfections.  
 
LNCaP, MCF7 and BRL4 were used to assay the cellular effects of screening hits on 
GH-signaling (Supplemental data). LNCaP was maintained in RPMI supplemented as 
above while MCF7 and BRL were cultured in DMEM as above. 
 
3.1.2.2 Bone Marrow Derived Macrophages 
To generate Bone Marrow Derived Macrophages (BMDM) from SOCS2-/- and 
wildtype mice (Paper III) the mice were euthanized and the femur and tibia of the hind 
legs were dissected and bone marrow cavities flushed out. Bone marrow cells were 
resuspended in DMEM supplemented as above with the addition of 10 mM HEPES and 
20-30% L929 conditioned media (as a source of macrophage colony-stimulating 
factor). Cells were passed through a cell strainer and cultured at 37°C, 5% CO2, for 6 
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days. Next, non-adherent cells were washed of; the cells were trypsinized, counted and 
re-plated for experimental purposes.        
 
 
3.2 WESTERN BLOT 
Western blotting is a robust and commonly used technique for the quantification and 
detection of proteins from various types of samples. It involves electrophoretic gel 
separation of the proteins in the sample, followed by transfer to a membrane, blocking 
and probing with antibodies directed at proteins of interest [347,348].  
 
Here, we have used Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) to separate denatured protein containing samples and transferred them to 
Polyvinylidene Fluoride (PVDF) membranes where they have been probed by 
antibodies to determine the presence, amount and post-translational modification status 
of proteins of interest (Paper I – III and Supplemental Data).   
 
 
3.3 IN VITRO UBIQUITINATION ASSAY 
The protocol for the in vitro ubiquitination assay was adapted from previously 
published protocols [270,349]. In order to evaluate the general ubiquitin ligase activity 
of SOCS2 HEK293T cells were transiently transfected with FLAG-tagged SOCS2 
(either wildtype or a mutant version), Elongin B and Elongin C (Paper I). Agarose 
beads coupled to an anti-FLAG antibody were used to immunoprecipitate FLAG-
SOCS2 and proteins binding to it. After washing the beads were incubated with the 
other components necessary for the ubiquitination reaction to occur, namely: E1 
activating enzyme, E2 conjugating enzyme (UbcH5b), ubiquitin and HA-tagged 
ubiquitin and an ATP-regenerating system containing ATP, creatinine phosphate and 
creatinine kinase. Incubation was carried out for 30 minutes at 30° C and the reaction 
was stopped by boiling the samples in protein electrophoresis loading buffer. Samples 
were analyzed by western blot and high-molecular weight conjugates of HA-ubiquitin 
and target proteins were visualized by probing the PVDF membranes with an anti-HA 
antibody.  
 
In order to evaluate SOCS2’s ability to ubiquitinate GHR HEK293T cells were 
transfected as above in concert with Myc-GHR. The reaction was carried out as 
described but stopped by the addition of EDTA. Proteins were eluted from the beads by 
incubation with a FLAG-peptide and GHR was immunoprecipitated from the eluate by 
an anti-Myc antibody. Following washing, samples were boiled in protein 
electrophoresis loading buffer and analyzed by western blot. GHR was detected by an 
anti-GHR antibody and ubiquitinated GHR was detected by the same anti-HA antibody 
as above. The principle for the method is depicted in Figure 3.1. 
 
 
 
 
 
 
 28 
 
 
 
 
Figure 3.1 In vitro ubiquitination assay for SOCS2. (1) FLAG-SOCS2 and bound proteins are 
immunoprecipitated from cell lysates of cells overexpressing FLAG-SOCS2 and Elongin B/C. (2) 
Ub, HA-tagged Ub, ATP, E1 and E2 enzymes are added. (3) Incubation for 30 minutes leads to 
the ubiquitination of SOCS2-bound target proteins. HA-Ub is incorporated in Poly-Ub chains. 
(4)The reaction is stopped and samples are either eluted or the total ubiquitination activity is 
visualized by western blot for HA. (5) Eluted samples can be re-precipitated with an antibody 
that recognizes the target. (6) Western blot detection with anti-HA or anti-Target antibodies 
can be used to identify the ubiquitinated forms of the target protein 
 
 
 
3.4 IN VITRO MUTAGENESIS OF PLASMID CONSTRUCTS 
Plasmid constructs used have been described earlier [195]. In order to investigate the 
importance of the various domains of SOCS2 several new constructs with point 
mutations in the SOCS-box and SH2 domain were generated (Paper I and II). The 
selection of which residues to mutate was based on previously reported point mutations 
in related proteins and SOCS2 [350-352].  
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Mutagenesis was carried out with the Quikchange II kit from Stratagene. In summary, 
PCR is carried out with a primer pair that contains the desired mutation in a central 
location and the plasmid that is to be mutated. The reaction generates linear, full length 
plasmids from the primers that contain the desired mutation. Next, the template, i.e. the 
original plasmid, is degraded by incubating the samples with DpnI, a restriction 
endonuclease that recognizes methylated sequences. The mutated plasmids are left 
intact since they are un-methylated. Finally, competent E. coli are transformed with the 
mixture and the mutated plasmids are purified from the bacteria and sequenced to 
ensure that the mutation is present as desired.  
 
 
3.5 LUCIFERASE ASSAY 
Luciferase reporter assays are frequently used to study gene expression, cellular 
signaling events and cell physiology. Applications include receptor activity, 
transcriptional activation and enzymatic activity [353]. In this study the pGL2 
Luciferase reporter vector was used; this vector carries the coding region of the 
wildtype firefly luciferase and it is designed for quantitative analysis of gene 
expression. We used the luciferase reporter assay to study the effect of SOCS2 levels 
and SOCS2 mutations on GH signaling (Paper II) and the vector we used had six copies 
of the GH response elements fused to the minimal TK promoter inserted upstream of 
the luciferase gene [354]. The vector was transfected into HEK293T cells in concert 
with different SOCS2 constructs and GHR. Once transfected, the cells were stimulated 
with GH overnight, lysed and the light intensities in the lysates was measured with a 
luminometer. A vector expressing the Renilla luciferase gene was cotransfected during 
all experiments to account for variations in transfection efficiency and both luciferases 
were measured simultaneously using a dual luciferase reporter assay system (Promega). 
 
 
3.6 METABOLIC PROFILING 
To assess the metabolic phenotype of wild type and SOCS2-/- mice, and the effect of 
the HFD challenge in both strains (Paper III) we utilized several well established 
methods described below. 
 
3.6.1 Whole body insulin sensitivity  
Whole body insulin sensitivity was assessed by intraperitoneal injections of glucose 
(Glucose Tolerance Test; ipGTT) and insulin (Insulin Tolerance Test; ipITT) followed 
by measurement of blood glucose levels over time using a glucometer (Paper III). This 
enables an assessment of: the rate whereby glucose is taken up (ipGTT) and the 
responsiveness to insulin (ipITT). A slow glucose uptake and a slow or small decrease 
in blood glucose in response to insulin are indicative of a diabetic state. Measurements 
of fasting glucose and fasting insulin were also taken and Homeostatic Model of Insulin 
Resistance (HOMA-IR) values were calculated as follows: fasting insulin (ng/ml) x 
fasting glucose (mM).  
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3.6.2 Hepatic triacylglyceride secretion 
To determine the Triacylglyceride (TAG) secretion rate mice were injected with Triton 
WR-1339 to block the hydrolysis of TAG (Paper III). Mice were fasted for 6 hours and 
injected via the tail vein (500 µg/g of body weight). Blood samples were taken at 0, 30, 
60 and 90 minutes and TAG concentration measured by an enzymatic colorimetric 
assay. The final values were corrected for body weight and the hepatic rate of TAG 
secretion was calculated from the slope of the curve and expressed as µmol TAG/min.    
 
 
3.7 SCREENING METHODS 
To screen for SOCS2 interacting compounds the EPIC platform was utilized as an 
initial screening method and hits were confirmed by iso-thermal titration calorimetry 
(supplemental data).  
  
3.7.1 The EPIC Screening Platform 
The initial screen was carried out on the EPIC screening platform (Corning) using 384 
well plates. The EPIC plates contain a waveguide at the bottom of the wells and the 
detection is based on changes in the refractory index of the liquid above the waveguide 
[355]. Briefly, the wavelength reflected from a well containing an immobilized protein 
is measured, next an analyte of interest is added and the plate re-measured. If binding to 
the immobilized protein occurs the refractory index will change and the reflected 
wavelength will increase. Each well is measured in two areas, one area which contains 
the immobilized protein and one reference area which lacks the amide coupling 
chemistry and thus no protein. The signal is calculated from the difference before and 
after addition of analyte corrected for the internal reference and measured in 
picometers.  
 
In our experiments recombinant human SOCS2-Elongin C-Elongin B complexes were 
covalently attached by amine-coupling to the bottom of the wells (20 mM Citrate pH 
6.0, 1 hour incubation), followed by washing in 100 mM Tris pH 7.5 to block further 
binding to the plate. Next, plates were incubated for 4 hour in assay buffer (50 mM 
HEPES, 100 mM NaCl, 1% DMSO) under temperature stable conditions, measured 
once before the addition of low molecular weight compounds and 25 minutes after the 
addition of compound. Experiments were carried out in quadruplicates and positive hits 
were retested against non-related protein (BSA) and in concentration gradients.  
   
3.7.2 Iso-Thermal Titration Calorimetry 
To characterize and confirm the interactions discovered by the EPIC screening platform 
Iso-thermal calorimetry was employed. The method measures changes in temperature 
induced by the binding of a ligand to another molecule (protein for instance), or rather 
the energy required to keep temperatures constant. An iso-thermal calorimeter consists 
of two separate cells, one for the sample and a reference cell. A molecule of interest is 
added to the sample cell at a known concentration and with a predetermined volume. 
The analyte or ligand to be assayed is titrated into the sample cell during stirring and 
the power required for keeping the temperature difference between the reference and 
sample cell constant over time is measured [356].  
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Our experiments were carried out on a MicroCal ITC 200 system (GE). 20 µM of 
recombinant SOCS2-Elongin C-Elongin B was loaded in the instrument and a 200 µM 
solution of the compound was injected in 11 increments of 3.5 µl each with 180 
seconds delay between injections, stirring speed 1000 rpm, temperature 25°C. All 
reagents were in a buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM 
TCEP and 2% DMSO. SOCS2 protein was dialyzed before the experiment and the 
final buffer used for dialysis was used for ITC; compound was originally dissolved in 
100% DMSO and diluted in the same buffer for ITC.  
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4 RESULTS 
 
4.1 SOCS2 REGULATES GHR TURNOVER - PAPER I 
At the start of this project SOCS2 was known to be a negative feedback regulator of 
GH signaling [315,316] and several mechanisms for its effects had been proposed 
[196]. The structure of SOCS2 had revealed that it was structurally homologous to 
other known ubiquitin ligases [264] and our hypothesis was that SOCS2 targeted the 
GHR or one of the other components of the JAK-STAT pathway for ubiquitination.    
 
The crystal structure of SOCS2 was solved in complex with Elongin B and C [264] and 
we therefore began by investigating if SOCS2 bound the other proteins present in 
related ubiquitin ligase complexes, Cullin5 and Rbx2. We found that SOCS2 indeed 
interacts with these two proteins and that the interaction with the two Elongins serves to 
stabilize SOCS2. Furthermore, we could show that SOCS2 exhibits ubiquitin ligase 
activity in vitro (Fig 4.1A) and that this activity was dependent on a functional SOCS-
box. Next, we investigated what effect SOCS2 has on the other components of the GH-
JAK-STAT pathway. Previous reports had determined that SOCS2 binds the GHR 
[119] and we investigated if this interaction was related to the ubiquitin ligase activity 
we noted earlier. We found that GHR levels are decreased in the presence of SOCS2 
and that this decrease can be halted by the addition of a proteasome inhibitor (Fig 
4.1B).   
 
 
 
Figure 4.1 SOCS2 regulates GHR levels by ubiquitination. (A) Western blot visualization of 
high molecular weight conjugates, containing HA-ubiquitin, that are formed when 
immunoprecipitated SOCS2 is incubated with E1, E2, Ubiquitin and ATP. (B) Western blot of 
GHR levels in the absence of SOCS2 (lane 1-3) and when SOCS2 is overexpressed (lanes 4-9). 
Lanes 7-9 are lysates from cells treated with proteasome inhibitor MG132. (C) Western blot 
showing SOCS2s effect on GHR levels when βTrCP is silenced.   
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Ger J. Strous and his group had already shown that GHR turnover was dependent on 
the ubiquitin proteasome system and had identified the ubiquitin ligase βTrCP as 
involved in GHR ubiquitination [205]. Our experiments showed that silencing of 
βTrCP indeed increase GHR levels, but that the effect of SOCS2 is independent on 
βTrCP and we concluded that the two ubiquitin ligases independently regulate the 
turnover of GHR (Fig 4.1C). We also co-precipitated SOCS2 and GHR and performed 
an in vitro ligase assay where we could observe SOCS2 dependent ubiquitination of the 
GHR.  
 
Figure 4.2 SOCS2 binds to the GHR and mediates its ubiquitination. (1) SOCS2 assembles an 
E3 ubiquitin ligase complex together with Elongin B and C, Cullin5 and Rbx2. Next, SOCS2 
binds to phosphorylated tyrosines on the GHR through its SH2 domain. (2) The GHR is poly-
ubiquitinated by an E2 conjugating enzyme. (3) The ubiquitinated GHR is degraded by the 
proteasome.    
 
We also noted that silencing of SOCS2 by siRNA in cells serves to increase GHR 
levels and that the SOCS2-/- mice have increased levels of GHR in the liver. Finally, we 
used GHR constructs with mutated tyrosine residues to determine which tyrosines that 
are crucial for SOCS2s regulation of GHR turnover and found that when Tyr487 is 
mutated GHR levels are less affected by SOCS2 and that when both Tyr487 and 
Tyr595 are mutated the GHR level is unaffected by overexpression of SOCS2.  
 
From the experiments conducted in this project we created a model for GHR regulation 
by SOCS2 which is summarized in Figure 4.2. We conclude that SOCS2 is an ubiquitin 
ligase that targets the GHR for proteasomal degradation and that this provides a 
mechanistic explanation for the physiological effects of SOCS2.   
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4.2 EFFECT OF THE SOCS2 S52N MUTANT ON GH SIGNALLING - 
PAPER II 
In the second paper we investigated the claim that a mutation of SOCS2, S52N, could 
explain a case of idiopathic acromegaly. A patient in Japan with distinctive signs of 
acromegaly were recently described [350]. Curiously, no evidence of elevated GH 
levels or hypothalamic tumors was detected. The patient exhibited a slight elevation in 
IGF-1 levels and genetic analysis revealed a heterozygous missense mutation in the 
SOCS2 gene where Ser52 had been replaced with Asn.  
 
To determine if the S52N substitution could be responsible for the reported phenotype 
we generated FLAG-SOCS2 S52N plasmid vectors and investigated the effect on GHR 
levels and signaling. In Paper I we noted that the stability of SOCS2 was affected when 
residues in the SH2 domain were mutated, however, the S52N mutation did not affect 
protein levels or the association to Elongin B and Cullin5. Next, we investigated if the 
previously demonstrated ability of SOCS2 to decrease GHR levels was altered for the 
S52N mutant but again we noted no discernible difference between the WT and the 
mutant construct. We also employed a luciferase based reporter assay system to 
quantify the effect on GH signaling but could not detect any significant difference 
between wildtype SOCS2 and the S52N mutant. Finally, we compared the binding 
surface of SOCS2 to those of related proteins and noted that a corresponding residue in 
SOCS3 is involved in a secondary interaction with JAK2 [357]. Since the residue was 
determined to not be of critical importance and SOCS2 is not known to inhibit JAK2 
directly we concluded that it is unlikely to interfere with GHR signaling.  
 
In summary, we were not able to see any effects of the SOCS2 S52N mutation on E3 
ligase complex formation, the regulation of GHR levels, GH signaling or association to 
the GHR. Based on our experiments and a structural assessment of SOCS2 we 
conclude that the mutation is silent and unlikely to explain the traits of the described 
patient.    
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4.3 SOCS2 IN HEPATIC STEATOSIS AND INSULIN RESISTANCE - 
PAPER III 
Despite the similarities in regards to growth between the SOCS2-/- mice and GH 
transgenic mice the SOCS2-/- mice display no clear metabolic phenotype while GH 
transgenic mice develop insulin resistance [73,358]. Previous studies from our group 
have indicated that the hepatic gene expression in SOCS2 mice is altered and that the 
changes only partially overlap with known GH induced changes [337]. This prompted 
us to more closely investigate the metabolic phenotype of SOCS2-/- mice. To gain 
better insight into the roles of SOCS2 and increased GH sensitivity in metabolic 
processes we provoked the mice with a HFD.  
 
Liver histology revealed that SOCS2-/- mice are protected from HFD induced hepatic 
steatosis. Hepatic expression of genes involved in TAG assembly was upregulated in 
SOCS2-/- mice on a HFD, and so was the hepatic in vivo TAG secretion rate. As hepatic 
steatosis is known to be associated with decreased insulin sensitivity we next performed 
insulin and glucose tolerance tests to investigate this. Surprisingly, we noted that the 
HFD fed SOCS2-/- mice displayed exacerbated insulin resistance compared to HFD fed 
wildtype mice. Fasting plasma insulin levels were increased in SOCS2-/- mice on HFD 
but we did not observe any differences in pancreatic levels of insulin or islet 
morphology, suggesting that the impaired insulin sensitivity is not caused by altered β 
cell function. Further analysis of the animals revealed that the HFD induced a marked 
upregulation of the hepatic expression of proinflammatory cytokines in the SOCS2-/- 
mice. Plasma levels of proinflammatory cytokines were also increased but we could not 
detect any enhanced macrophage infiltration of the liver, indicating that the normal 
population of liver resident macrophages was responsible for the increased secretion.  
 
In vitro studies of macrophages from SOCS2-/- mice demonstrated that deletion of 
SOCS2 leads to an increased responsiveness to TLR ligands. We assayed the response 
to LPS which triggers signaling through TLR4 and noted increased secretion of TNF-α, 
IL-1β and IFN-γ in SOCS2-/- macrophages in response to LPS. The phagocytic activity 
of the macrophages was also increased and the activation of NFκB, downstream of 
TLR4, augmented. To confirm our finding we assayed the levels of NFκB 
phosphorylation in vivo and found that they were also increased in SOCS2-/- compared 
to wildtype mice.   
 
From our experiments we concluded that SOCS2 has a protective role in the 
development of insulin resistance, likely by suppressing the release of proinflammatory 
cytokines that are known to contribute to the development of the condition. We 
describe an interesting model for future studies of the interplay between GH, 
inflammation and dietary factors in the regulation of glucose and lipid metabolism.    
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4.3.1 Regulation of TLR signaling by SOCS2 
In a follow up investigation to Paper III we have attempted to discern how SOCS2 
regulates macrophage activity and specifically how SOCS2 affects LPS-TLR4 
signaling. We again compared the LPS sensitivity of SOCS2-/- and wildtype BMDMs 
(Fig 4.3 A) and found that deletion of SOCS2 increases LPS induced TNF-α secretion. 
Analysis of the intracellular TLR4 signaling events revealed that the MyD88-dependent 
NFκB and p38 activation was increased in response to LPS (Fig 4.3 B), but that the 
MyD88-independent TLR4 activation of IRF3 was unchanged (Fig 4.3 C). To assess if 
the signaling difference persisted further upstream TAK1 phosphorylation levels were 
examined in the BMDMs but no SOCS2-dependent effects were discerned (Fig 4.3 D). 
 
 
 
Figure 4.3 SOCS2s effect on TLR4 signaling in Bone Marrow Derived Macrophages. (A) 
BMDMs from SOCS2KO and WT animals were stimulated with 10 ng/ml of LPS. Media was 
collected at the indicated timepoints and analyzed with a Milliplex kit to determine TNF-α 
levels in the media. The experiment was carried out in triplicates. (B), (C) and (D) BMDMs from 
SOCS2-/- and WT animals were stimulated with 10 ng/ml of LPS and lysed at the indicated 
timepoints. Whole cell lysates were analyzed by Western blot with the antibodies denoted in 
the figure.  
 
A lingering question from the published study was to what extent the observed 
phenotype was related to increased GH signaling and if any of the effects of SOCS2 
deletion were GH-independent. To evaluate the role of GH SOCS2-/- and wildtype 
BMDMs were treated with bovine GH 4 hours before they were stimulated with LPS. 
Media was collected after 16 hours and analyzed for TNF-α levels. We again saw 
increased secretion of TNF-α from SOCS2-/- macrophages in response to LPS but no 
GH effect (Fig 4.4 A).    
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Figure 4.4 Growth Hormone does not affect TNF-α secretion from BMDMs.  (A) BMDMs from 
SOCS2KO and WT animals were either pre-treated with 2 µg/ml of GH and 4 hours later 10 
ng/ml of LPS (GH+LPS) or only treated with 10 ng/ml of LPS (LPS). Media was collected 16 
hours after LPS stimulation and analyzed with an Elisa kit to determine TNF-α levels in the 
media. The experiment was carried out in quadruplicates. (B) BMDMs from SOCS2KO and WT 
animals were stimulated with 10 ng/ml of LPS and lysed at the indicated timepoints. Whole 
cell lysates were analyzed by Western blot with the antibodies denoted in the figure. 
 
It has been reported that SOCS2 would trigger Lys48-ubiquitination of TRAF6 and 
thereby regulate the downstream expression of cytokines. To assess if this might 
explain the increased TLR4 signaling we observe in SOCS2-/- macrophages we 
investigated the protein levels of TRAF6 and its interacting proteins IRAK4 and TAK1 
as well as levels of TLR4 (Fig 4.6 B). We did not observe any SOCS2 dependent 
changes in the total levels of these four proteins as one would expect if SOCS2 indeed 
causes Lys48-ubiquitination of them.    
 
As of yet we cannot explain how SOCS2 influences LPS signaling and the activation of 
macrophages. Given that GH does not seem to affect the response to LPS in our system 
it is unlikely that the effect is secondary to GH-signaling. Our hypothesis is that SOCS2 
has a direct target in the pathway and we are currently evaluating which proteins 
SOCS2 interacts with in cells stimulated with LPS by proteomic techniques.   
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4.4 SCREENING FOR SOCS2 MODULATING COMPOUNDS 
As part of our studies on SOCS2 actions we have attempted to screen for small, low 
molecular weight, drug-like compounds that can be used to modulate SOCS2 functions. 
The aim was to identify compounds that interact with SOCS2 and to test confirmed 
binders for their ability to affect SOCS2 activity. The screening was carried out in 
collaboration with Actar on their EPIC instrumentation (Corning) [359]. The screen 
was carried out against the compound library at Actar which contains low-molecular 
weight compounds that fulfill the Lipinski rules [360]. A little over 3000 compounds 
were screened against the recombinant SOCS2-Elongin B-Elongin C complex. Hits 
were tested against non-related protein (BSA) to exclude constitutive binders.  
 
From the initial screen 11 compounds were further evaluated for their ability to bind 
SOCS2 by Iso-Thermal Calorimetry (ITC) with the aid of the GE demo-lab. Of the 11 
compounds, 1 was confirmed to be a SOCS2 binder (Figure 4.5). The binding of this 
compound to SOCS2 is endothermic and the affinity was estimated to be in the range 
KD= 0.44 – 2.5 µM.  
 
 
Figure 4.5 Isothermal Calorimetry 
of recombinant SOCS2-Elongin B-
Elongin C and hit 10136. 
Calorimetry was carried out on a 
MicroCal ITC 200 system (GE).     
20 µM of recombinant SOCS2 was 
loaded in the instrument and a 
200 µM solution of the compound 
was injected in 11 increments of 
3.5 µl each with 180 seconds delay 
between injections, stirring speed 
1000 rpm. All reagents were in a 
buffer containing 50 mM HEPES, 
pH 7.5, 150 mM NaCl, 0.5 mM 
TCEP and 2% DMSO. SOCS2 
protein was dialyzed before the 
experiment and the final buffer 
used for dialysis was used for ITC; 
compound was originally dissolved 
in 100% DMSO and diluted in the 
same buffer for ITC. Injection of 
compound in buffer without 
SOCS2 was also investigated and 
yielded no signal. 
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To evaluate the effect on SOCS2 activity we began by investigating the compounds 
ability to infer with SOCS2s ubiquitin ligase activity in vitro. We added the compound 
to the ubiquitin ligase reaction [194] and evaluated it compared to control (Figure 4.6). 
We noted a significant inhibition of SOCS2 activity at a concentration of 20 µM of the 
compound.  
 
 
 
 
 
 
Figure 4.6 Hit 10136 decreases SOCS2s In vitro 
ubiquitin ligase activity. Quantitation of 
western blot visualization of high molecular 
weight (>100 kDa) HA-ubiquitin bands from in 
vitro ubiquitin ligase activity assay for SOCS2 
carried out in the presence of 20 or 2 µM of hit 
10136. Data displayed is relative to control (no 
compound) which is set to 1. N = 5 and error 
bars denote the 95% confidence interval of the 
mean.  
 
 
 
 
 
 
 
Next, we moved on to evaluate the compound in different cell systems that respond to 
GH by STAT5 phosphorylation. However, we were unable to see any effect of the 
compound even at high (100 µM) concentrations on GH signaling.  
 
Due to the lack of cellular effects we decided to halt our investigation. From the results 
achieved in the project we do however conclude that the activity of SOCS2 can be 
targeted and affected by low molecular weight compounds and that the hit we identified 
constitutes a possible scaffold for the design of such a compound.    
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5 DISCUSSION 
The important role of SOCS2 in the regulation of postnatal growth became obvious 
with the generation of the first SOCS2-/- mice [315]. No other SOCS protein or 
phosphatase produces such an obvious growth phenotype when deleted. While the 
effect has been known for some time, the underlying mechanism for this regulation has 
been a matter of debate. In Paper I we described how SOCS2 regulates GHR levels and 
thus terminates downstream signaling events. We demonstrated that SOCS2 
ubiquitinates the GHR which ultimately leads to its proteasomal degradation. The 
finding that SOCS2 is part of an ubiquitin ligase complex and that this activity is 
important for its effects on GH signaling was not controversial and confirmed previous 
suspicions [196,264].  
 
We also determined that the SOCS-box is required for the assembly of the E3 ligase 
complex and that interaction with Elongin C and B are important for the stability of the 
complex. Similarly, the SOCS-box of SOCS3 has been shown to be unstructured in the 
absence of Elongin B/C binding and to adopt a stable conformation once engaged by 
these two proteins [263]. The same is likely the case for SOCS2; we noted that point 
mutations in the SOCS-box domain led to unstable proteins present at low 
concentrations while deletion of the entire domain generated a protein with superior 
stability. The SH2 domain of SOCS2 is involved in the interaction with the target 
proteins but mutations in this domain also impact stability. Curiously, we also noted 
that both deletion of the N-terminal domain and point mutations in the SH2 domain 
abolishes the binding to Elongin C, but not the other components of the ECS complex. 
The finding could be an artifact, but similar results were obtained for SOCS6 in our lab 
[304]. An alternative explanation is that Cullin5/Elongin B complexes retain their 
ability to interact with the C-terminal domain of SOCS proteins. Indeed, independent 
motifs within the SOCS-box domain seem to mediate Cullin5 and Elongin C binding 
[236].       
 
In both Paper I and II we investigated the effects of SOCS2 SH2 domain mutants on 
GHR regulation. The mutant investigated in Paper I contains a mutation of Arg73. 
Corresponding residues in other SH2 domain containing proteins are involved in the 
interaction with the phosphotyrosine group and it is well conserved across species and 
for most human SH2 domains [265,304,357]. We noted that this mutation lead to 
decreased binding to the GHR, impaired regulation of GHR levels and diminished E3 
ligase activity, likely due to decreased affinity for phosphorylated tyrosine residues 487 
and 595 in the intracellular domain of GHR. On the other hand, the SOCS2R73E 
mutant retains some of its activity, suggesting that the SH2-phopshotyrosine interaction 
might not be the only interaction involved in SOCS2 target recognition. The 
observation that the SOCS2 dependent decrease in GHR levels was independent of 
ligand stimulation also suggests that SOCS2 might interact with inactive GHR and 
mediate its destruction. In Paper II we investigated the importance of Ser52, and 
specifically serine to asparagine substitution at this position. We could not observe any 
effect of the mutation suggesting that the position is of little relevance for SOCS2 
activity.  
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The domain that confers the most variation between the SOCS family members is the 
N-terminal domain. Little is known about this part of the proteins apart from that it 
contains the KIR domain for SOCS1 and 3 and a nuclear localization motif for SOCS6 
[361]. It has not been possible to determine the structure of any of the N-terminal 
domains in their entirety, likely since they adopt an unstructured conformation in the 
absence of a binding partner [362]. Further examination of this domain could increase 
our understanding of SOCS target interactions and possibly yield novel insight into the 
pleiotropic actions of the SOCS family.    
 
SOCS2 interaction with GHR has been demonstrated previously and in Paper I we 
showed that of the two phosphotyrosines that are known to interact with SOCS2, 
Tyr487 is of principal concern for its downregulation of GHR levels. Earlier studies 
from our group have noted corresponding effects on STAT5 signaling [195]. While our 
experiments in Paper I demonstrate that ubiquitin mediated proteasomal degradation of 
the GHR constitute one mechanism for SOCS2s regulation of GH signaling it does not 
preclude the contribution of other means of regulation. STAT5 interaction with the 
GHR has been shown to at least partially overlap with SOCS2 binding and even if they 
do not bind to the same tyrosine, steric hindrance by SOCS2 could still play a role. In 
particular, the unknown role of the N-terminus might confer such effects.  
 
Another means of SOCS2 regulation of the JAK-STAT pathway that has been 
suggested is that of direct JAK2 inhibition. Induction of SOCS expression by 17β-
estradiol (E2) leads to decreased GH induced JAK2 phosphorylation [325]. The effect 
was demonstrated to be dependent on SOCS2 and not SOCS1 or 3. This suggests that 
SOCS2 might directly inhibit JAK2. However, as we noted in Paper I, SOCS2 
mediated turnover of GHR is ligand independent and another possible explanation is 
that E2 induces SOCS2 expression, SOCS2 mediates GHR degradation and in the 
absence of GHR, JAK2 does not become phosphorylated in response to GH. Alas, a 
recent publication did demonstrate SOCS2 mediated inhibition of JAK2 kinase activity 
in vitro using recombinant proteins [363]. However, these studies did not include a 
measurement of direct interaction between SOCS2 and JAK2 and the biological 
relevance of these in vitro assays remains unknown. Previous publications have noted 
that SOCS2 overexpression does not affect JAK2 phosphorylation [314,322] and 
further experiments are needed to determine how SOCS2 affects JAK2 
phosphorylation.  
 
SOCS3 is a known inhibitor of JAK2 with a well characterized inhibitory mechanism. 
Another recent publication solved the structure of SOCS3 bound both to the gp130 
subunit of the IL-6 receptor and to JAK2 [357]. The structure revealed that several 
residues in the N-terminal end of the SH2 domain, among them Ala50, in SOCS3 is 
involved in the secondary interaction with JAK2. The corresponding residue in SOCS2 
is Ser52 and if SOCS2 indeed has a capacity for direct inhibition it could potentially be 
involved. This would in that case give credibility to the assumption that the SOCS2 
S52N mutation could promote an acromegalic phenotype [350]. However, SOCS3 
interaction with the GHR takes place in the membrane proximal part of the receptor, 
adjacent to the JAK2 binding site on the receptor while SOCS2 interacts in with 
membrane distal parts of the receptor [309]. It is of course possible that some part of 
SOCS2 could still interact with JAK2 but the notion seems unlikely. Furthermore, we 
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did not observe any increase in STAT5 signaling or MAPK activation by the S52N 
mutant which would be expected if it did indeed lead to diminished JAK2 activation.       
 
As detailed above, several different proteins regulate intracellular GH signaling. While 
all of these processes do not necessarily influence the actions of GH in all types of cells 
and under all conditions, it is clear that several mechanisms collaborate to attenuate GH 
signaling. The regulation of GHR turnover by the ubiquitin ligase βTrCP has been 
extensively studied and it is clear that βTrCP plays an important role in the regulation 
of GHR levels. Expression of βTrCP has not been demonstrated to be affected by GH 
and GHR endocytosis and degradation by βTrCP are independent of ligand stimulation 
[203]. This suggests that the role of βTrCP is to regulate receptor concentrations under 
basal conditions and thus the relative responsiveness of the individual cell to GH. 
SOCS proteins on the other hand, are upregulated in response to GH and through their 
SH2 domains they preferentially interact with activated receptors. Their role as 
negative feedback inhibitors is well documented and they contribute to the transient 
nature of GH induced STAT5 activation. SOCS1 and 3 are the first line of SOCS to be 
activated and they inhibit JAK2 which leads to a cessation of signaling. SOCS2 (and 
likely CIS) are upregulated more slowly, but once present they target the GHR. GHR 
depletion leads to a temporary GH resistant state and is likely important for the 
propagation of male specific GH pulses. CIS has been shown to be more constitutively 
upregulated in female livers, and could play a key role in the regulation of sex-specific, 
GH induced gene expression patterns [364]. The phenotype of the SOCS2-/- mice and 
our findings in Paper I clearly demonstrate the inhibitory effect of SOCS2 on GH 
signaling.  
 
In Paper III we describe the phenotype of SOCS2-/- mice under dietary stress. The 
exacerbated insulin resistance exhibited under these conditions matches the phenotype 
of GH transgenic mice fed a normal diet. The fact that a provocation in the form of 
HFD was required for this trait to appear underscores the difference between models of 
increased hormone secretion and increased hormone sensitivity. We observed that 
SOCS2-/- mice under normal circumstances have decreased plasma levels of GH 
compared to wildtype mice but retain normal levels of circulating IGF-1. GH 
transgenic mice on the other hand have elevated levels of both GH and IGF-1 [365]. 
Despite increased GH sensitivity the SOCS2-/- mice manage to decrease GH secretion, 
likely through negative feedback on the pituitary by IGF-1, which allows them to avoid 
the deleterious diabetogenic effects of elevated GH. The GH transgenic mice do not 
have the same ability to regulate their GH levels as GH is constitutively produced in 
these animals. The metabolic phenotypes of several other mouse models of altered GH 
sensitivity have also been investigated. Mice with a liver specific deletion of GHR, 
JAK2 or STAT5 spontaneously develop hepatic steatosis [75,366,367]. This is in line 
with what we observe in Paper III for the SOCS2-/- mice and strongly suggests that the 
lack of steatosis is due to increased GH sensitivity. Muscle specific deletion of GHR on 
the other hand protects against diet induced insulin resistance and reveals the tissue 
specific actions of GH [77]. Again, this correlates to the worsened insulin sensitivity 
observed in our model and provides a simple explanation for the phenotype: Complete 
deletion of SOCS2 leads to increased GH sensitivity throughout the body. In the liver 
the increased GH signaling counters steatosis while the diabetogenic effects of GH on 
the muscle leads to the observed decrease in insulin sensitivity. However, this model is 
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overly simplistic and overlooks the contribution of increased GH induced lipolysis and 
inflammation.   
 
An interesting and recent observation was that the mice with liver specific JAK2 
deletion are protected against HFD induced insulin resistance [368]. This differs from 
the phenotype of mice with liver specific GHR deletion that in addition to hepatic 
steatosis also develop insulin resistance. An explanation for the discrepancy is that 
JAK2 is utilized by several other cytokines and in its absence proinflammatory 
signaling is likely to be decreased. Again, this correlates to the heightened levels of 
proinflammatory cytokines we observed in the HFD fed SOCS2-/- mice and suggests 
that this phenotypic feature might be related to GH independent actions of SOCS2. In 
our follow-up study we investigated the effect of GH to try to elucidate if the increased 
secretion of TNF-α from SOCS2-/- macrophages is an indirect effect of SOCS2 and 
related to increased GH sensitivity. We could not observe any GH effect in our in vitro 
cultures and our current hypothesis is that SOCS2 directly regulates TLR4 signaling in 
macrophages. SOCS2 mediated Lys48 ubiquitination of TRAF6 was reported to 
attenuate TLR signaling but we have not observed any change in TRAF6 levels in 
macrophages from SOCS2-/- mice nor any effect on TAK1 phosphorylation [333]. 
Another putative target for SOCS2 regulation is Pyk2 which has been reported to be 
degraded by SOCS2 in NK cells and that has also been shown to regulate MyD88-
dependent TLR4 signaling [324,369]. Again, we have not observed any SOCS2 
dependent change in Pyk2 levels in our cell model and we are currently awaiting mass 
spectrometrical identification of potential LPS activated, SOCS2 interacting proteins 
for an unbiased overview of possible targets.  
 
While we have not noted any GH contribution to the augmented LPS signaling in 
SOCS2-/- macrophages, GH plays a part in the regulation of inflammatory signals. Cell 
based investigations have reported both pro and anti-inflammatory effects of GH 
[97,370]. However, it is worth noting that some are based on constitutive 
overexpression of GH while others use a single bolus dose for treatment which 
complicates comparative efforts due to the different gene expression patterns triggered 
by constant and transient GH exposure [371]. In vivo experiments have more 
consistently pointed towards an inflammation promoting role for GH. Transgenic GH 
mice suffer from chronic inflammation and short term GH treatment of healthy 
volunteers leads to increased plasma levels of proinflammatory cytokines [372,373]. As 
pointed out earlier, GH treatment is detrimental for critically ill patients and also 
suggests a proinflammatory role for GH. Interestingly, a recent publication showed that 
macrophage-specific deletion of the GHR in mice leads to exacerbated insulin 
resistance after high fat diet feeding [374]. The described phenotype resembles what we 
described for the SOCS2-/- mice and suggest that GH has an anti-inflammatory effect 
during dietary stress. A possible way to reconcile the two models is that in 
macrophages devoid of GHR there is likely to be low levels of SOCS2 which, as our 
experiments indicate, could lead to increased secretion of proinflammatory cytokines. 
Speculatively, SOCS2 might be considered an anti-inflammatory agent that counters 
the proinflammatory effects of GH, both by direct inhibition of GH signaling but also 
by decreasing proinflammatory cytokine production. This remains to be shown, but it is 
interesting to note that the macrophages from both macrophage-specific GHR deletion 
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and SOCS2-/- mice are both skewed towards M1 polarization suggesting a common link 
[327,374].     
 
In the supplementary data we give an account of our endeavors to screen for SOCS2-
modulating low molecular weight compounds. We have managed to identify a 
compound which affects SOCS2s ubiquitin ligase activity in vitro and work is on-going 
to improve its actions in cells. The concept of pharmaceutical amplification of hormone 
sensitivity holds promise of novel therapies that may be better suited for the treatment 
of hormone resistant states. A key example is diabetes where improving insulin 
sensitivity is central. GH replacement therapy is also associated with side effects and 
relying on endogenous hormone levels and improved sensitivity could decrease the 
occurrence of side effects.    
 
 
   45 
6 CONCLUSIONS AND FUTURE PERSPECTIVE 
This thesis explored the molecular basis for the actions of SOCS and its involvement in 
growth and metabolism. Conclusions are summarized below.  
 
I. SOCS2 forms an ubiquitin ligase complex with Elongin B and C, 
Cullin5 and Rbx2. The complex binds to and ubiquitinates the GHR 
which leads to its proteasomal degradation and a cessation of 
intracellular GH signaling.  
 
II. Mutation of the serine residue at position 52 to asparagine in SOCS 
does not impair SOCS2 mediated regulation of GH signaling. The 
finding does not support that the mutation contributes to the 
development of acromegaly.  
 
III. Deletion of SOCS2 protects against high fat diet induced hepatic 
steatosis but worsens insulin resistance. Increased levels of 
proinflammatory cytokines likely contribute to the phenotype.  
 
IV. SOCS2 is involved in the TLR4 mediated release of proinflammatory 
cytokines from macrophages in vitro. The effect is likely independent of 
GH.  
 
V. Screening for and identifying SOCS inhibitory molecules is possible 
and we have identified a substance that interferes with the actions of 
SOCS2 in vitro. Such inhibitors would be a useful research tool and 
could potentially constitute a novel class of therapeutic agents.  
     
A suggestion for future investigations based on the findings reported here is to focus on 
identifying novel targets of SOCS2 that may explain its effects. Several hormone and 
cytokine signaling pathways are known to be affected by SOCS2 but mechanisms 
remain unclear. A proper characterization of tissue specific effects of SOCS2 coupled 
with mass spectrometry to identify targets could prove fruitful in this endeavor. Of key 
importance is understanding the relationship of SOCS2 and GH in this regulation. 
Under what conditions is SOCS2 merely a negative regulator of GH actions and under 
what conditions is it a mediator of GH actions and in what way does SOCS2 act as an 
independent agent? Several interesting questions remain un-answered related to GH 
and altered GH sensitivity. Discoveries on the subject of genetically caused GH 
hypersensitivity due to SOCS2 mutations is likely to be presented in the future and it is 
also likely that altered GH sensitivity will be more firmly linked to disorders related to 
specific organ systems. Acquired disturbances of SOCS2 would require further 
investigations of the hormonal and environmental factors in control of its expression, 
studies of situations of genomic instability (e.g. tumors) where alteration of SOCS2 
would change growth and metabolism. Finally, the concept that SOCS proteins regulate 
inflammatory signals need to be further investigated. Ultimately one can foresee that 
the SOCS system will be adequately placed in the context of human physiology and 
pathology.   
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7 POPULAR SCIENCE SUMMARY 
Several bodily functions are controlled by hormones. Hormones are signaling 
molecules that are released from specialized glands and travel through the bloodstream 
to their intended targets. Once they reach their intended organ they interact with 
specialized receptors on the surface or inside of a target cell. Peptide hormones and 
cytokines are small proteins that are unable to enter the cell and therefore bind to 
surface receptors. The binding initiates a signaling cascade inside the cell which leads 
to the expression of hormone responsive genes. A well-studied example of peptide 
hormones is Growth Hormone (GH).  
 
It is important that the signaling inside the cell is not to low, but also not exaggerated, 
and several mechanisms for regulating the signaling therefore exist. An important 
protein family that regulates hormone and cytokine signals inside the cell is the 
Suppressors of Cytokine Signaling (SOCS) family. The genes for several SOCS 
proteins are activated by hormonal signals. This leads to production of SOCS proteins 
which will start to block the hormonal signaling. This thesis is concerned with the 
actions of SOCS2, and primarily its regulation of GH signaling. SOCS2 is known to 
inhibit GH signaling and if the SOCS2 gene is deleted in mice they increase in size by 
approximately 40%. 
 
In the first paper the detailed molecular mechanism for how SOCS2 blocks GH 
signaling is described. SOCS2 binds to several other proteins and together they form a 
large complex. This complex binds to the GH receptor and transfers a small protein 
called ubiquitin to the receptor. A chain of ubiquitin proteins eventually forms on the 
receptor, and this chain acts as a flag that marks the receptor for degradation. Flagged 
receptors are recognized by the proteasome which will begin to break them down. Once 
the receptors are degraded, the signaling ends. In the second paper a mutant version of 
SOCS2 is investigated. In this mutant the amino acid serine in position 52 is changed to 
an asparagine. This mutant has been reported in a patient with acromegaly, a syndrome 
normally associated with too much GH. However, the reported mutation does not affect 
SOCS2 activity or GH signaling and is therefore not likely to cause acromegaly.  
 
In the third paper the role of SOCS2 in metabolism is investigated. Mice where the 
SOCS2 gene is deleted (SOCS2 knock-out mice) were fed a high fat diet in order to 
induce diabetes. We found that compared to normal mice fed the same diet the SOCS2 
knock-out mice had reduced fat in their livers, which is a good sign, but they developed 
worsened insulin resistance. The reason for this is increased chronic inflammation and 
points to an important role for GH and SOCS2 in the regulation of inflammatory 
signals.   
 
In summary, we have elucidated the mechanism of action for SOCS2s regulation of GH 
signaling. We also report that the SOCS2 Ser52Asn mutant is fully functional and 
likely does not cause acromegaly. And finally, that SOCS2 knock-out mice are 
protected from diet induced fatty liver but instead become increasingly diabetic. The 
concept that SOCS2 regulates sensitivity to hormones can be of relevance to disorders 
of metabolism, growth and inflammation.         
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Många av kroppens funktioner styrs av hormoner. Hormoner är signalmolekyler som 
frisätts från specialiserade körtlar och färdas genom blodbanan till olika organ. När de 
når sitt avsedda organ så binder de till receptorer på ytan eller inuti sina målceller. 
Peptidhormoner och cytokiner är små proteiner som inte själva kan ta sig in i cellen och 
de binder därför till ytreceptorer. När de binder till sin receptor så påbörjas en 
signalkaskad inuti cellen vilket leder till att hormonaktiverade gener uttrycks. Ett 
välstuderat exempel på ett peptidhormon är tillväxthormon (GH). 
 
Det är viktigt att hormonsignalen inuti cellen inte är för svag eller överdriven utan 
lagom och flera mekanismer som reglerar signalen finns därför. En viktig familj av 
protein som reglerar hormon- och cytokinsignaler är familjen Suppressorer av 
Cytokinsignalering (SOCS). Generna för flera SOCS proteiner aktiveras av 
hormonsignaler. Detta leder till produktion av SOCS proteiner som börjar blockera 
signalen. Denna avhandling rör SOCS2 och framförallt dess reglering av GH signaler. 
Det är sedan tidigare känt att SOCS2 reglerar GH signalering och om genen för SOCS2 
tas bort i möss så ökar deras storlek med ungefär 40%. 
 
I den första artikeln så beskrivs den detaljerade molekylära mekanismen för hur SOCS2 
blockerar GH signallering. SOCS2 binder till ett flertal andra proteiner och tillsammans 
bildar de ett stort komplex. Detta komplex binder till GH receptorn och överför ett litet 
protein benämnt ubiquitin till receptorn. En kedja av ubiquitin bildas så småningom på 
receptorn och denna kedja fungerar som en flagga som markerar att receptorn ska 
brytas ned. Markerade receptorer känns igen av proteasomen som börjar bryta ned dem. 
När GH receptorerna har brutits ned så avstannar signalen. I den andra artikeln så 
undersöks en SOCS2 mutant. I denna mutant har aminosyran serin på position 52 bytts 
ut mot en asparagin. Det har rapporterats att den här mutationen är närvarande i en 
patient med akromegali, ett syndrom som normalt karakteriseras av för mycket GH. 
Våra resultat visar dock att mutationen inte påverkar SOCS2s aktivitet eller GH 
signaleringen och det är därför inte troligt att den orskar akromegali.  
 
I den tredje artikeln undersöks SOCS2s effekt på ämnesomsättningen. Möss där 
SOCS2-genen tagits bort (så kallade SOCS2-knock-out möss) gavs en diet med högt 
fettinnehåll för att framkalla diabetes. Jämfört med normala möss som fick samma diet 
så har SOCS2-knock-out mössen minskad leverförfettning, vilket brukar betraktas som 
ett gott tecken, men de utvecklar förvärrad insulinresistens. Vi fann att skälet för den 
förvärrade insulinresistensen är ökad kronisk inflammation i knock-out mössen vilket 
pekar på att GH och SOCS2 har en viktig roll i regleringen av inflammatoriska 
signaler.  
 
Sammanfattningsvis så har vi utrett mekanismen för hur SOCS2 reglerar GH 
signallering. Vi rapporterar även att mutationen Ser52Asn i SOCS2 inte påverkar 
SOCS2s aktivitet och troligtvis inte orsakar akromegali. Samt att SOCS2-knock-out 
möss är skyddade från dietorsakad leverförfettning men istället utvecklar förvärrad 
diabetes. Kunskap kring förändrad känslighet för GH kan vara av betydelse för 
metabola sjukdomar liksom för cancer och inflammatoriska tillstånd.      
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